CA2656788A1 - Controlled release composition comprising polyurethane elastomers - Google Patents
Controlled release composition comprising polyurethane elastomers Download PDFInfo
- Publication number
- CA2656788A1 CA2656788A1 CA002656788A CA2656788A CA2656788A1 CA 2656788 A1 CA2656788 A1 CA 2656788A1 CA 002656788 A CA002656788 A CA 002656788A CA 2656788 A CA2656788 A CA 2656788A CA 2656788 A1 CA2656788 A1 CA 2656788A1
- Authority
- CA
- Canada
- Prior art keywords
- polymer
- peg
- linear polymer
- ppg
- polymer according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4804—Two or more polyethers of different physical or chemical nature
- C08G18/4808—Mixtures of two or more polyetherdiols
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/65—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
- C08G18/66—Compounds of groups C08G18/42, C08G18/48, or C08G18/52
- C08G18/6666—Compounds of group C08G18/48 or C08G18/52
- C08G18/667—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38
- C08G18/6674—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/3203
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/73—Polyisocyanates or polyisothiocyanates acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/74—Polyisocyanates or polyisothiocyanates cyclic
- C08G18/75—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
- C08G18/758—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing two or more cycloaliphatic rings
Abstract
A linear polymer is obtained by reacting together a polyethylene glycol or polypropylene glycol; a PEG-PPG-PEG or PPG-PEG-PPG block copolymer; a difunctional amine or diol; and a diisocyanate. A controlled release composition comprises the polymer together with an active agent. Active agents of molecular weight 200 to 20,000 may be used.
Description
POLYURETHANE ELASTOMERS
The present invention relates to hydrophilic thermoplastic polyurethane elastomer polymers, suitable for the production of controlled release compositions for release of pharmaceutically active agents over a prolonged period of time.
Their elastomeric nature provides better comfort in use, for example, in pessaries, suppositories or vaginal rings.
Certain cross-linked polyurethane hydrogel polymers are known from European Patent Publications EP0016652 and EP0016654. These patent specifications describe cross-linked polyurethanes formed by reacting a polyethylene oxide of equivalent weight greater than 1500 with a polyfunctional isocyanate and a trifunctional compound reactive therewith, such as an alkane triol. The resultant cross-linked polyurethane polymers are water-swellable to form a hydrogel but are water-insoluble and may be loaded with water-soluble pharmaceutically active agents.
One particular polyurethane polymer is the reaction product of polyethylene glycol 8000, Desmodur (DMDI i.e. dicyclohexylmethane-4,4-diisocyanate) and 1,2,6-hexane triol and which has been used commercially for vaginal delivery of prostaglandins.
However, such polyurethane polymers possess a number of practical disadvantages. Whilst the use of a triol cross-linking agent is effective in providing polymers of relatively reproducible swelling characteristics, the percent swelling is typically 200-300% (i.e. the increase in weight of the swollen polymer divided by the weight of the dry polymer). Pharmaceutically active agents are loaded by contacting the polymer with an aqueous solution of pharmaceutically active agent, such that the solution becomes absorbed into the polymer, forming a hydrogel. The swollen polymer is then dried back to the chosen water content before use. A
consequence is that with the conventional cross-linked polyurethane, the degree of swelling limits the molecular weight of the pharmaceutically active agent which can be absorbed into the hydrogel structure to below about 3000 g/mol. A further disadvantage is that only water-soluble pharmaceutically active agents may be used. Finally, since the conventional cross-linked polyurethane polymer is essentially a non-thermoplastic polymer (thermoset), insoluble in both water and organic solvents, the further processing of the formed polymer into other solid forms, such as films, monolithic devices, foams, wafers, composites, sandwich structures, particles, pellets, foams or coatings, is not possible. In addition, the thermoset nature of the conventional cross-linked polyurethane polymer rules out the possibility of melt mixing drug with the polymer, in order to load the polymer with a suitable active agent without using solvents or water.
Certain thermoplastic polyurethane hydrogel polymers are known from patent Publication W02004029125. This patent specification describes linear thermoplastic polyurethanes formed by reacting a polyethylene glycol of molecular weight of greater than 4000 g/mol with a polyfunctional isocyanate and a bifunctional compound reactive therewith, such as an alkane diol or diamine. The resultant thermoplastic polyurethane polymers are water-swellable to form a hydrogel but are water-insoluble and may be loaded with water-soluble pharmaceutically active agents.
One particular polyurethane polymer is the reaction product of polyethylene glycol 8000, Desmodur (DMDI i.e. dicyclohexylmethane-4,4-diisocyanate) and 1,10-decane diol, which has shown percentage-swelling from 600% up to 1700% or even above.
This type of polymer has shown a suitability for diffusion loading and short-term delivery of relatively water-soluble drugs e.g. clindamycin phosphate, oxytocin, and misoprostol.
The present invention relates to hydrophilic thermoplastic polyurethane elastomer polymers, suitable for the production of controlled release compositions for release of pharmaceutically active agents over a prolonged period of time.
Their elastomeric nature provides better comfort in use, for example, in pessaries, suppositories or vaginal rings.
Certain cross-linked polyurethane hydrogel polymers are known from European Patent Publications EP0016652 and EP0016654. These patent specifications describe cross-linked polyurethanes formed by reacting a polyethylene oxide of equivalent weight greater than 1500 with a polyfunctional isocyanate and a trifunctional compound reactive therewith, such as an alkane triol. The resultant cross-linked polyurethane polymers are water-swellable to form a hydrogel but are water-insoluble and may be loaded with water-soluble pharmaceutically active agents.
One particular polyurethane polymer is the reaction product of polyethylene glycol 8000, Desmodur (DMDI i.e. dicyclohexylmethane-4,4-diisocyanate) and 1,2,6-hexane triol and which has been used commercially for vaginal delivery of prostaglandins.
However, such polyurethane polymers possess a number of practical disadvantages. Whilst the use of a triol cross-linking agent is effective in providing polymers of relatively reproducible swelling characteristics, the percent swelling is typically 200-300% (i.e. the increase in weight of the swollen polymer divided by the weight of the dry polymer). Pharmaceutically active agents are loaded by contacting the polymer with an aqueous solution of pharmaceutically active agent, such that the solution becomes absorbed into the polymer, forming a hydrogel. The swollen polymer is then dried back to the chosen water content before use. A
consequence is that with the conventional cross-linked polyurethane, the degree of swelling limits the molecular weight of the pharmaceutically active agent which can be absorbed into the hydrogel structure to below about 3000 g/mol. A further disadvantage is that only water-soluble pharmaceutically active agents may be used. Finally, since the conventional cross-linked polyurethane polymer is essentially a non-thermoplastic polymer (thermoset), insoluble in both water and organic solvents, the further processing of the formed polymer into other solid forms, such as films, monolithic devices, foams, wafers, composites, sandwich structures, particles, pellets, foams or coatings, is not possible. In addition, the thermoset nature of the conventional cross-linked polyurethane polymer rules out the possibility of melt mixing drug with the polymer, in order to load the polymer with a suitable active agent without using solvents or water.
Certain thermoplastic polyurethane hydrogel polymers are known from patent Publication W02004029125. This patent specification describes linear thermoplastic polyurethanes formed by reacting a polyethylene glycol of molecular weight of greater than 4000 g/mol with a polyfunctional isocyanate and a bifunctional compound reactive therewith, such as an alkane diol or diamine. The resultant thermoplastic polyurethane polymers are water-swellable to form a hydrogel but are water-insoluble and may be loaded with water-soluble pharmaceutically active agents.
One particular polyurethane polymer is the reaction product of polyethylene glycol 8000, Desmodur (DMDI i.e. dicyclohexylmethane-4,4-diisocyanate) and 1,10-decane diol, which has shown percentage-swelling from 600% up to 1700% or even above.
This type of polymer has shown a suitability for diffusion loading and short-term delivery of relatively water-soluble drugs e.g. clindamycin phosphate, oxytocin, and misoprostol.
However, such a high-swelling thermoplastic polyurethane polymer possesses many practical disadvantages. Due to the high weight content and block length of PEG, the polymer is only suitable for relatively short-term release (i.e.
controlled release from 10 min to only a few hours) of active agents, especially in the case of highly water-soluble drugs. In addition, the low hydrophobic content, i.e. low amount of hydrophobic compound e.g. decanediol (DD) or dodecanediol (DDD) makes the polymer inappropriate for hydrophobic drugs and thus restricts its use.
Hydrophilic and hydrophobic drugs need to have interactions with both of the phases in order for their release to be controlled by the polymer structure. Further, the imbalance between hydrophobic and hydrophilic compounds hampers microphase separation, which reduces the mechanical strength of the polymer in both the dry and wet state.
In addition, due to the high crystallinity of polymer and the formation of hard blocks, the final polymer is rigid and the processing temperature relatively high.
The swelling percentage of high-swelling thermoplastic polyurethanes is typically 200-1700% and is dependent on the PEG content and/or the length of PEG
block. Pharmaceutically active agents can be loaded by using the same method as described above for the conventional cross-linked polyurethane, as well as melt mixing drug and polymer. The release time and profiles obtained for the high swelling and crosslinked polyurethane polymers are, however, very similar.
Patent specification WO 94/22934 discloses the production of a linear random block copolymer from polyethylene oxide (number average molecular weight 1000 to 12,000), a diamine and a diisocyanate. Yu et al. Biomaterials 12 (1991) March, No.2, page 119-120 discloses the use of polyurethane hydrogels formed of polyethylene glycol (number average molecular weight of 5830) and a low molecular weight polypropylene glycol (molecular weight 425) and a diisocyanate. Patent specification US 4,202,880 discloses the production of polyurethanes from polyethylene glycol (molecular weight 400-20,000), an alkaline glycol containing from 2-6 carbon atoms and a diisocyanate. Patent specification US 4,235,988 is a similar disclosure, although the preferred PEG range is 600-6,000.
The object of the present invention is to provide a hydrophilic thermoplastic polyurethane elastomer, which can be processed and mixed with an active agent at the temperature below the degradation temperature of the active agent by using conventional polymer processing systems, e.g. melt mixer, extruder and injection moulding machine. An additional objective of the present invention is to enhance the melt viscosity, to increase elasticity and to lower the crystallinity of the polymer in order to apply conventional melt processing techniques e.g. extrusion and injection moulding, as well as different types of solvents to the formation of drug loaded resilient controlled release devices of any chosen shape.
The present invention is based on the discovery that thermoplastic polyurethane elastomers having suitable melt processing properties for drug loading and elasticity at body temperature, as well as suitable drug release characteristics, may be obtained by reacting a polyethylene glycol or polypropylene glycol with a diol or other difunctional compound, and a PPG-PEG-PPG or PEG-PPG-PEG block copolymer and a difunctional isocyanate.
PEG stands for polyethylene glycol; and PPG stands for polypropylene glycol.
In particular, the present invention provides a hydrophilic thermoplastic polyurethane elastomer polymer obtainable by reacting together:
(a) a polyethylene glycol or polypropylene glycol;
(b) a PEG-PPG-PEG or PPG-PEG-PPG block copolymer;
(c) a difunctional compound; and (d) a difunctional isocyanate.
The thermoplastic polyurethane elastomer produced is swellable in water to a specific degree, depending upon the ratio of the four components (a), (b), (c) and (d), for example from 1% up to 200% (e.g. 20 to 100%) thus better controlling the release of pharmaceutically active agents from the high-swelling, PEG-based linear polyurethane. The polymer of the invention is also soluble in certain organic solvents, such as dichioromethane, 1-methyl-2-pyrrolidone (NMP) and tetrahydrofuran, which allows the polymer to be dissolved and cast into films or coatings. It also allows thermally unstable active agents of poor water solubility but which are soluble in organic solvents, to be loaded into the polymer.
Due to the unique combination of starting components, these polyurethane elastomers have a composition that can control the release of active compounds from a few days up to a few months.
Polyether polyols contain the repeating ether linkage -R-O-R- and have two or more hydroxyl groups as terminal functional groups. They are manufactured by the =
catalysed addition of epoxides to an initiator (anionic ring-opening polymerisation).
The most important of the cyclic ethers by far are ethylene oxide and propylene oxide.
These oxides react with active hydrogen-containing compounds (initiators), such as water, glycols, polyols and amines. A catalyst may or may not be used.
Potassium hydroxide or sodium hydroxide is the basic catalyst most often employed. After the desired degree of polymerisation has been achieved, the catalyst is neutralized, removed by filtration and additives such as antioxidants are added.
A wide variety of compositions of varying structures, chain lengths and molecular weights is possible. By selecting the oxide or oxides, initiator, and reaction conditions and catalysts, it is possible to polymerise a series of polyether polyols that range from low-molecular-weight polyglycols to high-molecular-weight polymers.
Since these polymers contain repeating alkylene oxide units, they are often referred to as polyalkylene glycols or polyglycols. Most polyether polyols are produced for polyurethane applications.
Polyethylene glycols (PEG) contain the repeat unit (-CH2CH2O-) and are conveniently prepared by the addition of ethylene oxide to ethylene glycol to produce a difunctional polyethylene glycol structure HO(CHZCHZO)nH wherein n is an integer of varying size depending on the molecular weight of the polyethylene glycol.
Polyethylene glycols used in the present invention are generally linear polyethylene glycols i.e. diols having molecular weights of 200 to 35,000 g/mol. (generally 400 to 2000).
Polypropylene glycols (PPG) are polymers of propylene oxide and thus contain the repeat unit (-CH2(CH3)CH2O-). Polypropylene glycol has unique physical and chemical properties due to the co-occurance of both primary and secondary hydroxyl groups during polymerisation, and to the multiplicity of methyl side chains on the polymers. Conventional polymerisation of propylene glycol results in an atactic polymer. The isotactic polymers mainly exist in the laboratory.
Mixtures of atactic and isotactic polymers may also occur. PPG has many properties in common with polyethylene glycol. Polypropylene glycols of all molecular weights are clear, viscous liquids with a low pour point, and which show an inverse temperature-solubility relationship, along with a rapid decrease in water solubility as the molecular weight increases. The terminal hydroxyl groups undergo the typical reactions of primary and secondary alcohols. The secondary hydroxyl group of polypropylene glycols is not as reactive as the primary hydroxyl group in polyethylene glycols. PPG is used in many formulations for polyurethanes.
Polypropylene glycols used in the present invention are generally linear having molecular weights of 200 to 4000 g/mol, (generally 400 to 2000).
The invention also provides a method of producing the linear polymer, which comprises melting and drying PEG or PPG, and the block copolymer, together with the difunctional compound at a temperature of 85 C to 100 C under vacuum; and then adding the difunctional isocyanate.
The production of block copolymers (b), based on propylene oxide and ethylene oxide, can be initiated with ethylene glycol, glycerine, trimethylolethane, trimethylolpropane, pentaerythritol, sorbitol, sucrose and several other compounds.
Mixed and alternating block copolymers can also be produced. When the secondary hydroxyl groups of PPG are capped with ethylene oxides, block copolymers of PEG
and PPG with terminal primary hydroxyl groups are yield. The primary hydroxyl groups are more reactive with isocyanates than secondary hydroxyl groups. PEG-PPG-PEG and PPG-PEG-PPG copolymers used in the present invention are generally linear having molecular weight of 200 to 14,000 g/mol. The block copolymer appears to contribute to the non-crystalline elastomeric nature of the polymer of the invention.
The difunctional compound (c) is reactive with the difunctional isocyanate, and is typically a difunctional amine or diol. Diols in the range C5 to C20, preferably C8 to C15 are preferred. Thus, decanediol has been found to produce particularly good results. The diol may be a saturated or unsaturated diol. Branched diols may be used but straight chain diols are preferred. The two hydroxyl groups are generally on terminal carbon atoms. Preferred diols include 1,6-hexanediol, 1,10-decanediol, 1,12-dodecanediol and 1, 1 6-hexadecanediol.
The difunctional isocyanate (d) is generally one of the conventional diisocyanates, such as dicyclohexylmethane-4,4-diisocyanate, diphenylmethane-4,4-diisocyanate, 1,6-hexamethylene diisocyanate etc.
The equivalent weight ratio of the components (a), (b), (c) and (d) is generally in the range 0.01-1 to 0.01-1 to 1 to 1.02-3 respectively. Of course, the skilled man through reasonable experimentation would determine the best ratio of ingredients to give the desired properties. The amount of component (d) is generally equal to the combined amounts of (a), (b) and (c) to provide the correct stoichiometry.
The polymers are generally produced by melting and drying PEG or PPG, and PEG-PPG-PEG or PPG-PEG-PPG block copolymer together with the difimctional compound and a typical polyurethane catalyst (if used), e.g. ferric chloride, DABCO
and/or tin (II) octoate, at a temperature of 85 C to 100 C (e.g. 95 C) under vacuum to remove excess moisture; before the diisocyanate, e.g. DMDI or HMDI is added thereto. The polymerisation is carried out in a batch or alterrnatively a continuous reactor; or the reaction mixture is fed into moulds and reacted for a specified time.
After polymerisation the polymer is cooled down, pelletised or granulated and stored in a freezer for further analysis and processing.
The elastomeric properties of the thermoplastic polyurethane elastomers of the invention are due to two factors: microphase separation of hard and soft blocks; and the semicrystalline nature of the polymer, whose amorphous phase has a low glass transition temperature. Hard blocks form from the difunctional compound and diisocyanate. Soft blocks are PEG, PPG or copolymer. The elasticity may depend on the ratio of hard to soft blocks and may be represented by Shore hardness measurements.
The linear polymers of the present invention are soluble in certain organic solvents. This allows the polymer to be dissolved and the resultant solution cast to form films. The solution may also be employed for coating granules, tablets etc., in order to modify the polymer release properties. Alternatively, the solution can be poured into a non-solvent so as to precipitate polymer/active microparticles.
In addition, the polymer can be ground, chopped, pelletised and melted by using conventional techniques used for processing thermoplastic polymers.
Thus, the invention also provides a controlled release composition comprising the linear polymer together with an active agent. Any type of plastic processing equipment, e.g. extruder, injection moulding machine, compression moulding equipment and melt mixer can be used for mixing the polymer and active agent together and forming or reshape into any type of drug loaded device, e.g. a ring, pessary, patch, rod, spring or cone. The active agent may be a pharmaceutically active agent for human or animal use. It may also be any other agent where sustained release properties (e.g. algicides, fertilisers etc.) are required. The pharmaceutical solid dosage forms include suppositories, rings and pessaries for vaginal use, buccal inserts for oral administration, patches for transdermal administration etc.
These dosage forms are generally administered to the patient, retained in place until delivery of active agent has occurred and the spent polymer is then removed. The polymer may also be used for implants, which remain in the body; or for coating such implants (e.g. stents).
The polymer of the present invention is an amphiphilic thermoplastic polymer and is thus suitable for the uptake of hydrophilic and hydrophobic, low and high molecular weight pharmaceutically active agents (up to and exceeding a molecular weight of 3000 e.g. up to 10,000, up to 50,000, up to 100,000 or even up to 200,000).
Generally, the molecular weight of the active agent is in the range 200 to 20,000. A
wide variety of water-soluble pharmaceutically active substances such as those listed in EP0016652 may thus be incorporated. Furthermore, the linear polymers of the present invention may be loaded with pharmaceutically active hydrophilic and hydrophobic agents, which are poorly water-soluble, provided that these can be dissolved in a common solvent with the polymer. The resultant solution can then be cast into any desired solid form. In addition, the linear polymers of the present invention may be extrusion loaded or melt mixed with pharmaceutically active agents, which are thermally stable at the polymer processing temperature.
The release time of the present polymers may exceed 12 hrs, 24 hrs, 5 days, 10 days, 20 days or even 80 days for substantially complete release of available active agent.
The polyether polyol blends and copolymers used in the present invention are internal and melt rheology, softness and release rate modifiers. These types of low melting amphiphilic thermoplastic polyurethane polymers are particularly suitable for the melt loading of pharmaceutically active agent and melt processing of loaded polymer to pharmaceutical devices.
Pharmaceutically active agents of particular interest include:
Proteins e.g. interferon alpha, beta and gamma, insulin, human growth hormone, leuprolide; benzodiazepines e.g. midazolam; anti-migraine agents e.g.
triptophans, ergotamine and its derivatives; anti-infective agents e.g. azoles, bacterial vaginosis, candida; and ophthalmic agents e.g. latanoprost.
A detailed list of active agent includes H2 receptor antagonist, antimuscaririe, prostaglandin analogue, proton pump inhibitor, aminosalycilate, corticosteroid, chelating agent, cardiac glycoside, phosphodiesterase inhibitor, thiazide, diuretic, carbonic anhydrase inhibitor, antihypertensive, anti-cancer, anti-depressant, calcium channel blocker, analgesic, opioid antagonist, antiplatel, anticoagulant, fibrinolytic, statin, adrenoceptor agonist, beta blocker, antihistamine, respiratory stimulant, micolytic, expertorant, benzodiazepine, barbiturate, anxiolytic, antipsychotic, tricyclic anti depressant, 5HT, antagonist, opiate, 5HT, agonist, antiemetic, antiepileptic, dopaminergic, antibiotic, antifungal, anthelmintic, antiviral, antiprotozoal, antidiabetic, insulin, thyrotoxin, femal sex hormone, male sex hormone, antioestrogen, hypothalamic, pituitary hormone, posterior pituitary hormone antagonist, antidiuretic hormone antagonist, bisphosphonate, dopamine receptor stimulant, androgen, non-steroidal anti-inflammatory, immuno suppressant local anaesthetic, sedative, antipsioriatic, silver salt, topical antibacterial vaccine.
Embodiments of the present invention will now be described by way of examples below. The effects of type and ratios of PEG or PPG, PEG-PPG-PEG or PPG-PEG-PPG copolymer, diols and diisocyanates on the properties of polymers can be seen in the following Tables, Examples and Figures.
Figure 1 shows molecular weight as a function of polymerisation time for certain polymers; and Figure 2 to 5 show various active agent release profiles.
EXAMPLE 1. Polymer manufacture Various types of polyethylene glycols, polypropylene glycols, PEG-PPG-PEGs, PPG-PEG-PPGs, diols and diisocyanates, in a range of stoichiometric ratios were used to demonstrate their effect on the properties of the hydrophilic linear polyurethane elastomer polymers. PEG400, PEG900, PEG1000 and PEG2000 are polyethylene glycols having a molecular weight of 400, 900, 1000 and 2000 g/mol, respectively; PPG1000 and PPG2000 are polypropylene glycols having a molecular weight of 1000 and 2000g/mol; PEG-PPG-PEG1100 and PEG-PPG-PEG4400 are block copolymers having a molecular weight of 1100 and 4400 g/mol; PPG-PEG-PEG2000 is a block copolymer having a molecular weight of 2000 g/mol; DD is 1,10-decanediol and DDD is 1,12-dodecanediol; DMDI is dicyclohexylmethane-4,4-diisocyanate and HMDI is 1,6-hexamethylene diisocyanate; FeC13 is Ferric chloride, DABCO is triethylene diamine and SnOct2 is Stannous octoate.
Polymers were produced by applying the polymerisation method described in WO patent Publication W02004029125. The PEG, PPG, PEG-PPG-PEG and/or PPG-PEG-PPG were melted and vacuum dried at 95 C along with the diol and the catalyst (if used) in a rotary-evaporator for an hour at a pressure below 1 mbar. At this point the dried mixture was fed into a reactor prior to the diisocyanate addition. The manufactured polymers are shown in Table 1.
A E
ry 3 00 00 00 00 00 00 00 00 00 00 00 00 rr A E L
IC \G ~O "O IC I'O , , I I I I I
iG N N N N N N
O
pca O O
A E L
O O I I I O O
N N N N
A L
3 v v~ ~ v v v v v v v~ v v C7 0 ~o v ~o ~o ,~
a p~ ~ p00 O ~ . I . O N.-r L O O O O O O
N pi 3 O O O O O O O O
O O . . . O O 0 O O O
GO N N N N N N N N
co W p ~O ~O ~t '~ ct ~ E L O O O O O O O O
W 3 ~ i . . . ~ O O i i ~ ~
N
O
O O ~ O O O O O O N,--~
Cd E L O O O O O O
O a 3 O O o 0 0 0 0 o O O O
~ o o , o 0 0 0 0 0 , , , , , O O O
~ O O O N O O O O N N N
~-+
h td - - N N N ~ ~ . . . N
O U L O O O C O
ir a ~ ~~ ~ ~ O O i i i N
~
~ dr~UAWr~C7* -~ ~~Ca* Gaa 6~ y L L L L L L y, ~ L L yL~ Zi L L L L
c}~.+ ~'., E a! ~ a) 6~ a> 6~ a) L ~ a~ a~ y, L a~ a~ a) G~
~ õ E 8 E E E 6 E E E E E E~ 6 E E E 6 ~
~ p; z o 0 0 0 0 0 0 o 0 0 o 0 0 0 0 a a a a a a, a w o. a a 0 a a a a, a y +
zoo E ~ -= N `n . * ~.
EXAMPLE 2. Polymerisation reaction as a function of time The effect of polymerisation time on the polymer produced was investigated using triple detection Size Exclusion Chromatography (SEC). Molecular weight determination as a function of polymerisation time was carried out for Polymers B
and C, see Figure 1 below. The molecular weight of the polymer will determine the rheology, melt flow and mechanical properties of the polymer. Therefore the importance of determining molecular weight values is evident.
EXAMPLE 3. The effect of the catalyst on the polymerisation reactions The polymerisations were performed as in Example 1 but the ferric chloride was replaced by DABCO and SnOct2 for Polymer N (Table 1); while DABCO alone was used for Polymer M (Table 1). Polymer H (Table 1) was prepared in the absence of a catalyst.
EXAMPLE 4. The use of different diisocyanates The polymerisations were performed as in Example I but the DMDI was replaced by HMDI for polymers F, G, H, I, K, L, M, N, 0, P, Q and R in Table 1.
EXAMPLE 5. Solubility of uolymers in different solvents A number of polymers from Table 1 were dissolved in different solvents in order to find suitable solvents. The solubility tests were carried out for 24 hours at room temperature (RT). The solubility results for the selected polymers are shown in Table 2.
Table 2. Polymer solubility in selected solvents.
Polymer DCM THF DCM/TEA THF/TEA
Name RT 35 C RT 35 C
Polymer A - YES - -Polymer B - YES - -Polymer C - YES - -Polymer D - YES - -Polymer P YES YES YES YES
DCM dichloromethane THF tetrahydrofuran TEA triethyl amine EXAMPLE 6. Swelling capacity of polymers in different solvents The swelling determinations for a number of selected polymers were carried out in water, ethanol, isopropyl alcohol (IPA) and in a 50% mixture of IPA/water in order to measure the amount of solvent absorbed by the polymer. The results were calculated based on the average swelling of 10 specimens and are shown in Table 3.
The formula used for the calculations is shown below:
%Swelling Weight - Dry Weight Swelling = x 100 Dry Weight Table 3. Percent swelling of the selected polymers in different swelling media (water, ethanol, IPA and 50% IPA/water).
Polymer % Swelling in % Swelling in % Swelling in % Swelling in Name Water Ethanol IPA 50% IPA/water Polymer A 2.5 133 113 68 Polymer B 2.5 89 73 71 Polymer C 43 N/A 130 206 EXAMPLE 7. Shore hardness testine (elasticitv measurement) The manufactured polymers were tested for Shore hardness using durometers A and D. Durometers A and D are generally used to measure elasticity of soft and hard rubber, respectively. These measurements are well known to the skilled person in the field. The results are presented as the average of four measurements and are presented in Table 4.
Table 4. Shore hardness values determined for the manufactured polymers.
Polymer Durometer A Durometer D
Name Max Hardness Creep (15 sec) Max Hardness Creep (15 sec) Polymer A 97.6 0.4 50.6 7.6 Polymer B 97.5 2.6 56.5 12.5 Polymer C 81.4 2.6 27.4 4.3 Polymer D N/A N/A N/A N/A
Polymer E N/A N/A N/A N/A
Polymer F 95.8 0.0 49.0 3.6 Polymer G 97.0 0.3 56.6 2.3 Polymer H*1 97.0 0.0 60.5 4.0 Polymer 1 97.0 2.5 53.8 4.8 Polymer J N/A N/A N/A N/A
Polymer K 88.3 20.0 22.8 10.0 Polymer L 85.3 0.9 39.3 1.5 Polymer M*2 94.8 0.4 45.3 1.5 Polymer N*3 95.4 3.8 40.3 6.3 Polymer 0 89.8 1.8 39.8 4.1 Polymer P 88.0 3.8 28.1 1.6 Polymer Q 60.8 3.9 N/A N/A
Pol mer R 87.0 2.0 29.8 1.8 Experimental conditions:
Temperature 21 C
Relative Humidity %RH 39 EXAMPLE 8. Polymer films manufactured by compression moulding A number of selected polymers from Table 1 were dried over night under vacuum prior to the processing. The upper and lower plate temperatures of the compression moulding machine were set at the target processing temperature.
Two Teflon sheets were placed between the mould and the hot plates. The melting time was 3-5 minutes followed by a 30 -120 seconds holding under pressure (170-200 bars). A predetermined amount of polymer was used to fill the mould. After cooling to room temperature the samples (pessary devices with dimensions 30mm x 10mm x 1 mm) were mechanically punched out and kept in the freezer for further analysis. The film processing conditions are shown in Table 5.
Table 5. Thermal processing of the manufactured polymers using compression moulding.
Polymer Temperature Cylinder Melting Pressure Mould ( C) Pressure Time Time Thickness (Bar) (s) (s) (mm) Polymer A* 160 200 240 120 1.0 Polymer A* 160 200 210 120 1.0 Polymer A 150 200 120 60 0.25 Polymer C 130 200 180 60 0.4 EXAMPLE 9. Drug loadinE - extrusion Selected polymers were loaded with two different active compounds:
fluconazole and oxybutynin. A 16mm co-rotating twin-screw laboratory extruder was used for loading the polymers. Table 6 shows the drug loading conditions.
Table 6. Extrusion loading conditions used for the fluconazole loaded devices.
Polymer Drug Drug Screw speed Temperature profile from Name wt% r m feed to die C
Polymer A* Fluconazole 20 40 55-95-120-120-120 Polymer A* Fluconazole 50 40 55-95-115-115-115 Pol mer A Fluconazole 20 60 80-110-110-110-110 Pol mer A Fluconazole 50 60 103-113-115-115-115 Pol mer A Oxybutynin 5 60 80-115-115-115-115 Pol mer A Oxybutynin l0 40 90-110-110-110-110 Pol mer A Oxybutynin 15 60 80-110-110-110-110 Polymer B Oxybutynin 5 50 132-132-132-132-132 Polymer B Oxybutynin 10 40 133-133-133-133-136 Pol mer C Fluconazole 20 60 95-115-115-115-115 Polymer C Oxybutynin 5 60 85-100-105-105-105 Polymer C Oxybutynin 10 50 80-100-105-105-105 Pol mer C Oxybutynin 15 40 80-100-110-110-110 Two different batches of the same polymer composition (Polymer A and A*) were loaded with fluconazole in two different drug amounts in order to prove the reproducibility of the polymerisation process. Release results were found to be reproducible.
The quantity of the active compound loaded into the polymers was based on the required therapeutic dosage.
EXAMPLE 10. Drug release studies - Effect of polymer In vitro drug release properties of the extrusion loaded polymers were determined by dissolution studies. The amount of fluconazole and oxybutynin released from the extrusion loaded polymers was investigated by using dissolution method based on the USP paddle method for short term release and incubator shaker method with Erlenmeyer bottles for long term release. USP paddle technique is comprised of an automated UV dissolution system where a Distek (2100C model) dissolution paddle (speed 50rpm) is connected to a Unicam UV 500 spectrophotometer via an Icalis peristaltic pump. The system is operated using Dsolve software. In the incubator shaker method the samples were taken manually and the Unicam UV 500 spectrophotometer was used to analyse the samples.
Experimental conditions:
Temperature 37 C
Dissolution media 500ml of deionised degassed water In this example the effect of the polymer structure on the release of fluconazole was investigated. Polymer A and C were loaded with 20wt%
fluconazole and Polymer A, B and C were loaded with 5% of oxybutynin using extrusion techniques. The release of fluconazole and oxybutynin varied depending on the polymer matrix, see Figure 2a and 2b.
EXAMPLE 11. Drug release studies - Effect of drug When the drug type was changed different release profiles were obtained.
Fluconazole and oxybutynin were loaded into Polymer A. Normalised dissolution profiles are shown in Figure 3. The same dissolution method as in Example 10 was used to determine the release curves.
EXAMPLE 12. Drug release studies - Effect of drug amount The effect of increasing loading content was investigated by dissolution studies. The effect of different drug contents on the release properties of Polymer A
was investigated and is shown in Figure 4. The fluconazole loading was increased from 20wt% to 50wt%. The same dissolution method as in Example 10 was used to determine the release curves.
EXAMPLE 13. Drug release studies - Comparison with high-swelling polymers The fluconazole release profile obtained for Polymer A and Polymer C were compared with the release profiles obtained for a crosslinked and a linear high-swelling polyurethane polymer, see Figure 5. The diffusion loaded crosslinked polymer (crosslinked l7wt% fluconazole) was from patent EP0016652/EP0016654.
While the linear high swelling polymer was from patent W02004029125 and was loaded using diffusion (high %SW 17wt% fluconazole) as well as extrusion techniques (high %SW 20wt% fluconazole). The same dissolution method as in Example 10 was used to determine the release curves. These new polymers can provide an excellent control over drug release, see Figure 5.
controlled release from 10 min to only a few hours) of active agents, especially in the case of highly water-soluble drugs. In addition, the low hydrophobic content, i.e. low amount of hydrophobic compound e.g. decanediol (DD) or dodecanediol (DDD) makes the polymer inappropriate for hydrophobic drugs and thus restricts its use.
Hydrophilic and hydrophobic drugs need to have interactions with both of the phases in order for their release to be controlled by the polymer structure. Further, the imbalance between hydrophobic and hydrophilic compounds hampers microphase separation, which reduces the mechanical strength of the polymer in both the dry and wet state.
In addition, due to the high crystallinity of polymer and the formation of hard blocks, the final polymer is rigid and the processing temperature relatively high.
The swelling percentage of high-swelling thermoplastic polyurethanes is typically 200-1700% and is dependent on the PEG content and/or the length of PEG
block. Pharmaceutically active agents can be loaded by using the same method as described above for the conventional cross-linked polyurethane, as well as melt mixing drug and polymer. The release time and profiles obtained for the high swelling and crosslinked polyurethane polymers are, however, very similar.
Patent specification WO 94/22934 discloses the production of a linear random block copolymer from polyethylene oxide (number average molecular weight 1000 to 12,000), a diamine and a diisocyanate. Yu et al. Biomaterials 12 (1991) March, No.2, page 119-120 discloses the use of polyurethane hydrogels formed of polyethylene glycol (number average molecular weight of 5830) and a low molecular weight polypropylene glycol (molecular weight 425) and a diisocyanate. Patent specification US 4,202,880 discloses the production of polyurethanes from polyethylene glycol (molecular weight 400-20,000), an alkaline glycol containing from 2-6 carbon atoms and a diisocyanate. Patent specification US 4,235,988 is a similar disclosure, although the preferred PEG range is 600-6,000.
The object of the present invention is to provide a hydrophilic thermoplastic polyurethane elastomer, which can be processed and mixed with an active agent at the temperature below the degradation temperature of the active agent by using conventional polymer processing systems, e.g. melt mixer, extruder and injection moulding machine. An additional objective of the present invention is to enhance the melt viscosity, to increase elasticity and to lower the crystallinity of the polymer in order to apply conventional melt processing techniques e.g. extrusion and injection moulding, as well as different types of solvents to the formation of drug loaded resilient controlled release devices of any chosen shape.
The present invention is based on the discovery that thermoplastic polyurethane elastomers having suitable melt processing properties for drug loading and elasticity at body temperature, as well as suitable drug release characteristics, may be obtained by reacting a polyethylene glycol or polypropylene glycol with a diol or other difunctional compound, and a PPG-PEG-PPG or PEG-PPG-PEG block copolymer and a difunctional isocyanate.
PEG stands for polyethylene glycol; and PPG stands for polypropylene glycol.
In particular, the present invention provides a hydrophilic thermoplastic polyurethane elastomer polymer obtainable by reacting together:
(a) a polyethylene glycol or polypropylene glycol;
(b) a PEG-PPG-PEG or PPG-PEG-PPG block copolymer;
(c) a difunctional compound; and (d) a difunctional isocyanate.
The thermoplastic polyurethane elastomer produced is swellable in water to a specific degree, depending upon the ratio of the four components (a), (b), (c) and (d), for example from 1% up to 200% (e.g. 20 to 100%) thus better controlling the release of pharmaceutically active agents from the high-swelling, PEG-based linear polyurethane. The polymer of the invention is also soluble in certain organic solvents, such as dichioromethane, 1-methyl-2-pyrrolidone (NMP) and tetrahydrofuran, which allows the polymer to be dissolved and cast into films or coatings. It also allows thermally unstable active agents of poor water solubility but which are soluble in organic solvents, to be loaded into the polymer.
Due to the unique combination of starting components, these polyurethane elastomers have a composition that can control the release of active compounds from a few days up to a few months.
Polyether polyols contain the repeating ether linkage -R-O-R- and have two or more hydroxyl groups as terminal functional groups. They are manufactured by the =
catalysed addition of epoxides to an initiator (anionic ring-opening polymerisation).
The most important of the cyclic ethers by far are ethylene oxide and propylene oxide.
These oxides react with active hydrogen-containing compounds (initiators), such as water, glycols, polyols and amines. A catalyst may or may not be used.
Potassium hydroxide or sodium hydroxide is the basic catalyst most often employed. After the desired degree of polymerisation has been achieved, the catalyst is neutralized, removed by filtration and additives such as antioxidants are added.
A wide variety of compositions of varying structures, chain lengths and molecular weights is possible. By selecting the oxide or oxides, initiator, and reaction conditions and catalysts, it is possible to polymerise a series of polyether polyols that range from low-molecular-weight polyglycols to high-molecular-weight polymers.
Since these polymers contain repeating alkylene oxide units, they are often referred to as polyalkylene glycols or polyglycols. Most polyether polyols are produced for polyurethane applications.
Polyethylene glycols (PEG) contain the repeat unit (-CH2CH2O-) and are conveniently prepared by the addition of ethylene oxide to ethylene glycol to produce a difunctional polyethylene glycol structure HO(CHZCHZO)nH wherein n is an integer of varying size depending on the molecular weight of the polyethylene glycol.
Polyethylene glycols used in the present invention are generally linear polyethylene glycols i.e. diols having molecular weights of 200 to 35,000 g/mol. (generally 400 to 2000).
Polypropylene glycols (PPG) are polymers of propylene oxide and thus contain the repeat unit (-CH2(CH3)CH2O-). Polypropylene glycol has unique physical and chemical properties due to the co-occurance of both primary and secondary hydroxyl groups during polymerisation, and to the multiplicity of methyl side chains on the polymers. Conventional polymerisation of propylene glycol results in an atactic polymer. The isotactic polymers mainly exist in the laboratory.
Mixtures of atactic and isotactic polymers may also occur. PPG has many properties in common with polyethylene glycol. Polypropylene glycols of all molecular weights are clear, viscous liquids with a low pour point, and which show an inverse temperature-solubility relationship, along with a rapid decrease in water solubility as the molecular weight increases. The terminal hydroxyl groups undergo the typical reactions of primary and secondary alcohols. The secondary hydroxyl group of polypropylene glycols is not as reactive as the primary hydroxyl group in polyethylene glycols. PPG is used in many formulations for polyurethanes.
Polypropylene glycols used in the present invention are generally linear having molecular weights of 200 to 4000 g/mol, (generally 400 to 2000).
The invention also provides a method of producing the linear polymer, which comprises melting and drying PEG or PPG, and the block copolymer, together with the difunctional compound at a temperature of 85 C to 100 C under vacuum; and then adding the difunctional isocyanate.
The production of block copolymers (b), based on propylene oxide and ethylene oxide, can be initiated with ethylene glycol, glycerine, trimethylolethane, trimethylolpropane, pentaerythritol, sorbitol, sucrose and several other compounds.
Mixed and alternating block copolymers can also be produced. When the secondary hydroxyl groups of PPG are capped with ethylene oxides, block copolymers of PEG
and PPG with terminal primary hydroxyl groups are yield. The primary hydroxyl groups are more reactive with isocyanates than secondary hydroxyl groups. PEG-PPG-PEG and PPG-PEG-PPG copolymers used in the present invention are generally linear having molecular weight of 200 to 14,000 g/mol. The block copolymer appears to contribute to the non-crystalline elastomeric nature of the polymer of the invention.
The difunctional compound (c) is reactive with the difunctional isocyanate, and is typically a difunctional amine or diol. Diols in the range C5 to C20, preferably C8 to C15 are preferred. Thus, decanediol has been found to produce particularly good results. The diol may be a saturated or unsaturated diol. Branched diols may be used but straight chain diols are preferred. The two hydroxyl groups are generally on terminal carbon atoms. Preferred diols include 1,6-hexanediol, 1,10-decanediol, 1,12-dodecanediol and 1, 1 6-hexadecanediol.
The difunctional isocyanate (d) is generally one of the conventional diisocyanates, such as dicyclohexylmethane-4,4-diisocyanate, diphenylmethane-4,4-diisocyanate, 1,6-hexamethylene diisocyanate etc.
The equivalent weight ratio of the components (a), (b), (c) and (d) is generally in the range 0.01-1 to 0.01-1 to 1 to 1.02-3 respectively. Of course, the skilled man through reasonable experimentation would determine the best ratio of ingredients to give the desired properties. The amount of component (d) is generally equal to the combined amounts of (a), (b) and (c) to provide the correct stoichiometry.
The polymers are generally produced by melting and drying PEG or PPG, and PEG-PPG-PEG or PPG-PEG-PPG block copolymer together with the difimctional compound and a typical polyurethane catalyst (if used), e.g. ferric chloride, DABCO
and/or tin (II) octoate, at a temperature of 85 C to 100 C (e.g. 95 C) under vacuum to remove excess moisture; before the diisocyanate, e.g. DMDI or HMDI is added thereto. The polymerisation is carried out in a batch or alterrnatively a continuous reactor; or the reaction mixture is fed into moulds and reacted for a specified time.
After polymerisation the polymer is cooled down, pelletised or granulated and stored in a freezer for further analysis and processing.
The elastomeric properties of the thermoplastic polyurethane elastomers of the invention are due to two factors: microphase separation of hard and soft blocks; and the semicrystalline nature of the polymer, whose amorphous phase has a low glass transition temperature. Hard blocks form from the difunctional compound and diisocyanate. Soft blocks are PEG, PPG or copolymer. The elasticity may depend on the ratio of hard to soft blocks and may be represented by Shore hardness measurements.
The linear polymers of the present invention are soluble in certain organic solvents. This allows the polymer to be dissolved and the resultant solution cast to form films. The solution may also be employed for coating granules, tablets etc., in order to modify the polymer release properties. Alternatively, the solution can be poured into a non-solvent so as to precipitate polymer/active microparticles.
In addition, the polymer can be ground, chopped, pelletised and melted by using conventional techniques used for processing thermoplastic polymers.
Thus, the invention also provides a controlled release composition comprising the linear polymer together with an active agent. Any type of plastic processing equipment, e.g. extruder, injection moulding machine, compression moulding equipment and melt mixer can be used for mixing the polymer and active agent together and forming or reshape into any type of drug loaded device, e.g. a ring, pessary, patch, rod, spring or cone. The active agent may be a pharmaceutically active agent for human or animal use. It may also be any other agent where sustained release properties (e.g. algicides, fertilisers etc.) are required. The pharmaceutical solid dosage forms include suppositories, rings and pessaries for vaginal use, buccal inserts for oral administration, patches for transdermal administration etc.
These dosage forms are generally administered to the patient, retained in place until delivery of active agent has occurred and the spent polymer is then removed. The polymer may also be used for implants, which remain in the body; or for coating such implants (e.g. stents).
The polymer of the present invention is an amphiphilic thermoplastic polymer and is thus suitable for the uptake of hydrophilic and hydrophobic, low and high molecular weight pharmaceutically active agents (up to and exceeding a molecular weight of 3000 e.g. up to 10,000, up to 50,000, up to 100,000 or even up to 200,000).
Generally, the molecular weight of the active agent is in the range 200 to 20,000. A
wide variety of water-soluble pharmaceutically active substances such as those listed in EP0016652 may thus be incorporated. Furthermore, the linear polymers of the present invention may be loaded with pharmaceutically active hydrophilic and hydrophobic agents, which are poorly water-soluble, provided that these can be dissolved in a common solvent with the polymer. The resultant solution can then be cast into any desired solid form. In addition, the linear polymers of the present invention may be extrusion loaded or melt mixed with pharmaceutically active agents, which are thermally stable at the polymer processing temperature.
The release time of the present polymers may exceed 12 hrs, 24 hrs, 5 days, 10 days, 20 days or even 80 days for substantially complete release of available active agent.
The polyether polyol blends and copolymers used in the present invention are internal and melt rheology, softness and release rate modifiers. These types of low melting amphiphilic thermoplastic polyurethane polymers are particularly suitable for the melt loading of pharmaceutically active agent and melt processing of loaded polymer to pharmaceutical devices.
Pharmaceutically active agents of particular interest include:
Proteins e.g. interferon alpha, beta and gamma, insulin, human growth hormone, leuprolide; benzodiazepines e.g. midazolam; anti-migraine agents e.g.
triptophans, ergotamine and its derivatives; anti-infective agents e.g. azoles, bacterial vaginosis, candida; and ophthalmic agents e.g. latanoprost.
A detailed list of active agent includes H2 receptor antagonist, antimuscaririe, prostaglandin analogue, proton pump inhibitor, aminosalycilate, corticosteroid, chelating agent, cardiac glycoside, phosphodiesterase inhibitor, thiazide, diuretic, carbonic anhydrase inhibitor, antihypertensive, anti-cancer, anti-depressant, calcium channel blocker, analgesic, opioid antagonist, antiplatel, anticoagulant, fibrinolytic, statin, adrenoceptor agonist, beta blocker, antihistamine, respiratory stimulant, micolytic, expertorant, benzodiazepine, barbiturate, anxiolytic, antipsychotic, tricyclic anti depressant, 5HT, antagonist, opiate, 5HT, agonist, antiemetic, antiepileptic, dopaminergic, antibiotic, antifungal, anthelmintic, antiviral, antiprotozoal, antidiabetic, insulin, thyrotoxin, femal sex hormone, male sex hormone, antioestrogen, hypothalamic, pituitary hormone, posterior pituitary hormone antagonist, antidiuretic hormone antagonist, bisphosphonate, dopamine receptor stimulant, androgen, non-steroidal anti-inflammatory, immuno suppressant local anaesthetic, sedative, antipsioriatic, silver salt, topical antibacterial vaccine.
Embodiments of the present invention will now be described by way of examples below. The effects of type and ratios of PEG or PPG, PEG-PPG-PEG or PPG-PEG-PPG copolymer, diols and diisocyanates on the properties of polymers can be seen in the following Tables, Examples and Figures.
Figure 1 shows molecular weight as a function of polymerisation time for certain polymers; and Figure 2 to 5 show various active agent release profiles.
EXAMPLE 1. Polymer manufacture Various types of polyethylene glycols, polypropylene glycols, PEG-PPG-PEGs, PPG-PEG-PPGs, diols and diisocyanates, in a range of stoichiometric ratios were used to demonstrate their effect on the properties of the hydrophilic linear polyurethane elastomer polymers. PEG400, PEG900, PEG1000 and PEG2000 are polyethylene glycols having a molecular weight of 400, 900, 1000 and 2000 g/mol, respectively; PPG1000 and PPG2000 are polypropylene glycols having a molecular weight of 1000 and 2000g/mol; PEG-PPG-PEG1100 and PEG-PPG-PEG4400 are block copolymers having a molecular weight of 1100 and 4400 g/mol; PPG-PEG-PEG2000 is a block copolymer having a molecular weight of 2000 g/mol; DD is 1,10-decanediol and DDD is 1,12-dodecanediol; DMDI is dicyclohexylmethane-4,4-diisocyanate and HMDI is 1,6-hexamethylene diisocyanate; FeC13 is Ferric chloride, DABCO is triethylene diamine and SnOct2 is Stannous octoate.
Polymers were produced by applying the polymerisation method described in WO patent Publication W02004029125. The PEG, PPG, PEG-PPG-PEG and/or PPG-PEG-PPG were melted and vacuum dried at 95 C along with the diol and the catalyst (if used) in a rotary-evaporator for an hour at a pressure below 1 mbar. At this point the dried mixture was fed into a reactor prior to the diisocyanate addition. The manufactured polymers are shown in Table 1.
A E
ry 3 00 00 00 00 00 00 00 00 00 00 00 00 rr A E L
IC \G ~O "O IC I'O , , I I I I I
iG N N N N N N
O
pca O O
A E L
O O I I I O O
N N N N
A L
3 v v~ ~ v v v v v v v~ v v C7 0 ~o v ~o ~o ,~
a p~ ~ p00 O ~ . I . O N.-r L O O O O O O
N pi 3 O O O O O O O O
O O . . . O O 0 O O O
GO N N N N N N N N
co W p ~O ~O ~t '~ ct ~ E L O O O O O O O O
W 3 ~ i . . . ~ O O i i ~ ~
N
O
O O ~ O O O O O O N,--~
Cd E L O O O O O O
O a 3 O O o 0 0 0 0 o O O O
~ o o , o 0 0 0 0 0 , , , , , O O O
~ O O O N O O O O N N N
~-+
h td - - N N N ~ ~ . . . N
O U L O O O C O
ir a ~ ~~ ~ ~ O O i i i N
~
~ dr~UAWr~C7* -~ ~~Ca* Gaa 6~ y L L L L L L y, ~ L L yL~ Zi L L L L
c}~.+ ~'., E a! ~ a) 6~ a> 6~ a) L ~ a~ a~ y, L a~ a~ a) G~
~ õ E 8 E E E 6 E E E E E E~ 6 E E E 6 ~
~ p; z o 0 0 0 0 0 0 o 0 0 o 0 0 0 0 a a a a a a, a w o. a a 0 a a a a, a y +
zoo E ~ -= N `n . * ~.
EXAMPLE 2. Polymerisation reaction as a function of time The effect of polymerisation time on the polymer produced was investigated using triple detection Size Exclusion Chromatography (SEC). Molecular weight determination as a function of polymerisation time was carried out for Polymers B
and C, see Figure 1 below. The molecular weight of the polymer will determine the rheology, melt flow and mechanical properties of the polymer. Therefore the importance of determining molecular weight values is evident.
EXAMPLE 3. The effect of the catalyst on the polymerisation reactions The polymerisations were performed as in Example 1 but the ferric chloride was replaced by DABCO and SnOct2 for Polymer N (Table 1); while DABCO alone was used for Polymer M (Table 1). Polymer H (Table 1) was prepared in the absence of a catalyst.
EXAMPLE 4. The use of different diisocyanates The polymerisations were performed as in Example I but the DMDI was replaced by HMDI for polymers F, G, H, I, K, L, M, N, 0, P, Q and R in Table 1.
EXAMPLE 5. Solubility of uolymers in different solvents A number of polymers from Table 1 were dissolved in different solvents in order to find suitable solvents. The solubility tests were carried out for 24 hours at room temperature (RT). The solubility results for the selected polymers are shown in Table 2.
Table 2. Polymer solubility in selected solvents.
Polymer DCM THF DCM/TEA THF/TEA
Name RT 35 C RT 35 C
Polymer A - YES - -Polymer B - YES - -Polymer C - YES - -Polymer D - YES - -Polymer P YES YES YES YES
DCM dichloromethane THF tetrahydrofuran TEA triethyl amine EXAMPLE 6. Swelling capacity of polymers in different solvents The swelling determinations for a number of selected polymers were carried out in water, ethanol, isopropyl alcohol (IPA) and in a 50% mixture of IPA/water in order to measure the amount of solvent absorbed by the polymer. The results were calculated based on the average swelling of 10 specimens and are shown in Table 3.
The formula used for the calculations is shown below:
%Swelling Weight - Dry Weight Swelling = x 100 Dry Weight Table 3. Percent swelling of the selected polymers in different swelling media (water, ethanol, IPA and 50% IPA/water).
Polymer % Swelling in % Swelling in % Swelling in % Swelling in Name Water Ethanol IPA 50% IPA/water Polymer A 2.5 133 113 68 Polymer B 2.5 89 73 71 Polymer C 43 N/A 130 206 EXAMPLE 7. Shore hardness testine (elasticitv measurement) The manufactured polymers were tested for Shore hardness using durometers A and D. Durometers A and D are generally used to measure elasticity of soft and hard rubber, respectively. These measurements are well known to the skilled person in the field. The results are presented as the average of four measurements and are presented in Table 4.
Table 4. Shore hardness values determined for the manufactured polymers.
Polymer Durometer A Durometer D
Name Max Hardness Creep (15 sec) Max Hardness Creep (15 sec) Polymer A 97.6 0.4 50.6 7.6 Polymer B 97.5 2.6 56.5 12.5 Polymer C 81.4 2.6 27.4 4.3 Polymer D N/A N/A N/A N/A
Polymer E N/A N/A N/A N/A
Polymer F 95.8 0.0 49.0 3.6 Polymer G 97.0 0.3 56.6 2.3 Polymer H*1 97.0 0.0 60.5 4.0 Polymer 1 97.0 2.5 53.8 4.8 Polymer J N/A N/A N/A N/A
Polymer K 88.3 20.0 22.8 10.0 Polymer L 85.3 0.9 39.3 1.5 Polymer M*2 94.8 0.4 45.3 1.5 Polymer N*3 95.4 3.8 40.3 6.3 Polymer 0 89.8 1.8 39.8 4.1 Polymer P 88.0 3.8 28.1 1.6 Polymer Q 60.8 3.9 N/A N/A
Pol mer R 87.0 2.0 29.8 1.8 Experimental conditions:
Temperature 21 C
Relative Humidity %RH 39 EXAMPLE 8. Polymer films manufactured by compression moulding A number of selected polymers from Table 1 were dried over night under vacuum prior to the processing. The upper and lower plate temperatures of the compression moulding machine were set at the target processing temperature.
Two Teflon sheets were placed between the mould and the hot plates. The melting time was 3-5 minutes followed by a 30 -120 seconds holding under pressure (170-200 bars). A predetermined amount of polymer was used to fill the mould. After cooling to room temperature the samples (pessary devices with dimensions 30mm x 10mm x 1 mm) were mechanically punched out and kept in the freezer for further analysis. The film processing conditions are shown in Table 5.
Table 5. Thermal processing of the manufactured polymers using compression moulding.
Polymer Temperature Cylinder Melting Pressure Mould ( C) Pressure Time Time Thickness (Bar) (s) (s) (mm) Polymer A* 160 200 240 120 1.0 Polymer A* 160 200 210 120 1.0 Polymer A 150 200 120 60 0.25 Polymer C 130 200 180 60 0.4 EXAMPLE 9. Drug loadinE - extrusion Selected polymers were loaded with two different active compounds:
fluconazole and oxybutynin. A 16mm co-rotating twin-screw laboratory extruder was used for loading the polymers. Table 6 shows the drug loading conditions.
Table 6. Extrusion loading conditions used for the fluconazole loaded devices.
Polymer Drug Drug Screw speed Temperature profile from Name wt% r m feed to die C
Polymer A* Fluconazole 20 40 55-95-120-120-120 Polymer A* Fluconazole 50 40 55-95-115-115-115 Pol mer A Fluconazole 20 60 80-110-110-110-110 Pol mer A Fluconazole 50 60 103-113-115-115-115 Pol mer A Oxybutynin 5 60 80-115-115-115-115 Pol mer A Oxybutynin l0 40 90-110-110-110-110 Pol mer A Oxybutynin 15 60 80-110-110-110-110 Polymer B Oxybutynin 5 50 132-132-132-132-132 Polymer B Oxybutynin 10 40 133-133-133-133-136 Pol mer C Fluconazole 20 60 95-115-115-115-115 Polymer C Oxybutynin 5 60 85-100-105-105-105 Polymer C Oxybutynin 10 50 80-100-105-105-105 Pol mer C Oxybutynin 15 40 80-100-110-110-110 Two different batches of the same polymer composition (Polymer A and A*) were loaded with fluconazole in two different drug amounts in order to prove the reproducibility of the polymerisation process. Release results were found to be reproducible.
The quantity of the active compound loaded into the polymers was based on the required therapeutic dosage.
EXAMPLE 10. Drug release studies - Effect of polymer In vitro drug release properties of the extrusion loaded polymers were determined by dissolution studies. The amount of fluconazole and oxybutynin released from the extrusion loaded polymers was investigated by using dissolution method based on the USP paddle method for short term release and incubator shaker method with Erlenmeyer bottles for long term release. USP paddle technique is comprised of an automated UV dissolution system where a Distek (2100C model) dissolution paddle (speed 50rpm) is connected to a Unicam UV 500 spectrophotometer via an Icalis peristaltic pump. The system is operated using Dsolve software. In the incubator shaker method the samples were taken manually and the Unicam UV 500 spectrophotometer was used to analyse the samples.
Experimental conditions:
Temperature 37 C
Dissolution media 500ml of deionised degassed water In this example the effect of the polymer structure on the release of fluconazole was investigated. Polymer A and C were loaded with 20wt%
fluconazole and Polymer A, B and C were loaded with 5% of oxybutynin using extrusion techniques. The release of fluconazole and oxybutynin varied depending on the polymer matrix, see Figure 2a and 2b.
EXAMPLE 11. Drug release studies - Effect of drug When the drug type was changed different release profiles were obtained.
Fluconazole and oxybutynin were loaded into Polymer A. Normalised dissolution profiles are shown in Figure 3. The same dissolution method as in Example 10 was used to determine the release curves.
EXAMPLE 12. Drug release studies - Effect of drug amount The effect of increasing loading content was investigated by dissolution studies. The effect of different drug contents on the release properties of Polymer A
was investigated and is shown in Figure 4. The fluconazole loading was increased from 20wt% to 50wt%. The same dissolution method as in Example 10 was used to determine the release curves.
EXAMPLE 13. Drug release studies - Comparison with high-swelling polymers The fluconazole release profile obtained for Polymer A and Polymer C were compared with the release profiles obtained for a crosslinked and a linear high-swelling polyurethane polymer, see Figure 5. The diffusion loaded crosslinked polymer (crosslinked l7wt% fluconazole) was from patent EP0016652/EP0016654.
While the linear high swelling polymer was from patent W02004029125 and was loaded using diffusion (high %SW 17wt% fluconazole) as well as extrusion techniques (high %SW 20wt% fluconazole). The same dissolution method as in Example 10 was used to determine the release curves. These new polymers can provide an excellent control over drug release, see Figure 5.
Claims (16)
1. A linear polymer obtainable by reacting together (a) a polyethylene glycol or polypropylene glycol;
(b) a PEG-PPG-PEG or PPG-PEG-PPG block copolymer;
(c) a difunctional compound; and (d) a difunctional isocyanate.
(b) a PEG-PPG-PEG or PPG-PEG-PPG block copolymer;
(c) a difunctional compound; and (d) a difunctional isocyanate.
2. A linear polymer according to claim 1, wherein the polyethylene glycol is a linear polyethylene glycol having a molecular weight of 400 to 2000.
3. A linear polymer according to claim 1, wherein the polypropylene glycol is a linear polypropylene glycol having an molecular weight of 400 to 2000.
4. A linear polymer according to any preceding claim, wherein the block copolymer has a molecular weight of 200 to 14,000.
5. A linear polymer according to any preceding claim, wherein the difunctional compound (c) is a diol.
6. A linear polymer according to claim 5, wherein the diol is a C5 to C20 diol.
7. A linear polymer according to claim 6, wherein the diol is a C8 to C15 diol.
8. A linear polymer according to claim 6 wherein the diol is 1,6-hexanediol, 1,10-decanediol, 1,12-dodecanediol or 1,16-hexadecanediol.
9. A linear polymer according to any preceding claim, wherein the difunctional isocyanate (d) is dicyclohexylmethane-4,4-diisocyanate, diphenylmethane-4,4-diisocyanate, or 1,6-hexamethylene diisocyanate.
10. A linear polymer according to any preceding claim, wherein the equivalent weight ratio of the components (a), (b), (c) and (d) is in the range 0.01-1 to 0.01 - 1 to 1.02-3 respectively.
11. A method of producing a linear polymer according to any preceding claim, which comprises melting and drying PEG or PPG, and the block copolymer, together with the difunctional compound at a temperature of 85°C to 100°C
under vacuum;
and then adding the difunctional isocyanate.
under vacuum;
and then adding the difunctional isocyanate.
12. A controlled release composition, which comprises the linear polymer of claim 1 together with an active agent.
13. A composition according to claim 12, which has been processed into a solid dosage form.
14. A composition according to claim 13 in the form of a suppository, ring or pessary for vaginal use, a bucchal insert, or a transdermal patch.
15. A composition according to claim 13 in the form of an implant.
16. A composition according to any of claims 12 to 15, wherein the active agent has a molecular weight of 200 to 20,000.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0613638.6A GB0613638D0 (en) | 2006-07-08 | 2006-07-08 | Polyurethane elastomers |
| GB0613638.6 | 2006-07-08 | ||
| PCT/GB2007/002415 WO2008007046A1 (en) | 2006-07-08 | 2007-06-27 | Polyurethane elastomers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2656788A1 true CA2656788A1 (en) | 2008-01-17 |
| CA2656788C CA2656788C (en) | 2015-01-27 |
Family
ID=36926730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2656788A Active CA2656788C (en) | 2006-07-08 | 2007-06-27 | Controlled release composition comprising polyurethane elastomers |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8361272B2 (en) |
| EP (1) | EP2038325B1 (en) |
| JP (2) | JP5307710B2 (en) |
| CN (1) | CN101484495B (en) |
| AT (1) | ATE498643T1 (en) |
| AU (1) | AU2007274119B2 (en) |
| BR (1) | BRPI0713481B8 (en) |
| CA (1) | CA2656788C (en) |
| DE (1) | DE602007012545D1 (en) |
| DK (1) | DK2038325T3 (en) |
| ES (1) | ES2363704T3 (en) |
| GB (1) | GB0613638D0 (en) |
| PL (1) | PL2038325T3 (en) |
| PT (1) | PT2038325E (en) |
| WO (1) | WO2008007046A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
| US8637629B2 (en) * | 2007-01-18 | 2014-01-28 | Lubrizol Advanced Materials, Inc. | High moisture vapor transmissive polyurethanes |
| EP2244782A4 (en) | 2008-01-25 | 2011-09-14 | Univ Utah Res Found | Linear order release polymer |
| US20090233887A1 (en) * | 2008-03-12 | 2009-09-17 | Shalaby Shalaby W | Hydroswellable, Segmented, Aliphatic Polyurethanes and Polyurethane Ureas |
| FI123146B (en) * | 2009-10-01 | 2012-11-30 | Bayer Schering Pharma Oy | An intrauterine system |
| US8940799B2 (en) * | 2010-03-25 | 2015-01-27 | Medtronic Xomed, Inc. | Adjusting drug loading in polymeric materials |
| US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
| KR101993786B1 (en) | 2010-11-12 | 2019-06-28 | 더 유니버시티 오브 유타 리서치 파운데이션 | Intravaginal devices for controlled delivery of lubricants |
| WO2013013172A1 (en) * | 2011-07-20 | 2013-01-24 | The University Of Utah Research Foundation | Intravaginal devices for drug delivery |
| EP2826463B1 (en) * | 2012-03-13 | 2019-05-15 | Sumitomo Seika Chemicals CO. LTD. | Cosmetic composition |
| WO2015044415A1 (en) * | 2013-09-30 | 2015-04-02 | Universiteit Gent | Polyurethanes as oral drug delivery platform |
| TW201527422A (en) * | 2013-10-15 | 2015-07-16 | Lubrizol Advanced Mat Inc | Thermoplastic polyurethanes made with tin-free catalysts |
| JP5955922B2 (en) * | 2013-11-11 | 2016-07-20 | 三洋化成工業株式会社 | Polyurethane resin for water equivalent phantom materials |
| US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
| KR102283445B1 (en) * | 2013-12-10 | 2021-07-28 | 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 | Highly resilient thermoplastic polyurethanes |
| MX2017005597A (en) | 2014-10-31 | 2017-06-23 | Lubrizol Advanced Mat Inc | Thermoplastic polyurethane film for delivery of active agents to skin surfaces. |
| EP3017809A1 (en) * | 2014-11-07 | 2016-05-11 | Ferring B.V. | Drug-device unit containing quinagolide |
| US11202986B2 (en) * | 2017-10-09 | 2021-12-21 | Ali Pournaghshband Isfahani | Plasticization-resistant polyurethane membrane and preparation method thereof |
| JP7185641B2 (en) * | 2017-12-04 | 2022-12-07 | 住友精化株式会社 | Composition for volatile material dissipation |
| WO2023031218A1 (en) | 2021-08-31 | 2023-03-09 | Ferring B.V. | Diagnosis and treatment of ectopic endometriosis |
Family Cites Families (325)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE505703C2 (en) | 1995-12-15 | 1997-09-29 | Polyrand Ab | Linear block polymer comprising urea and urethane groups, process for producing linear block polymers and use of the block polymers as implants |
| US3916898A (en) | 1964-05-20 | 1975-11-04 | Searle & Co | Administration of medicaments and the like |
| US3487068A (en) | 1966-12-16 | 1969-12-30 | Upjohn Co | Lincomycin-2-phosphates,7-substituted compounds and salts thereof |
| US3830907A (en) | 1968-04-22 | 1974-08-20 | Searle & Co | Compositions for the sustained release of 17alpha-ethyl-19-nortestosterone |
| US3860701A (en) | 1968-04-22 | 1975-01-14 | Searle & Co | Method for use and compositions of 11-lower alkyl steroids and drug delivery system for the controlled elution of 11-lower alkyl steroids |
| US3565991A (en) | 1968-04-22 | 1971-02-23 | Searle & Co | Methods for use and compositions of 17alpha-ethyl-19-nortestosterone and carriers for the sustained release of steroids |
| US3639157A (en) | 1968-07-18 | 1972-02-01 | Bayer Ag | Process for finishing textile materials with a polymer of a vinyl compound and the reaction product of a polyol and an organic polyisocyanate |
| US3896819A (en) | 1969-04-01 | 1975-07-29 | Alejandro Zaffaroni | IUD having a replenishing drug reservoir |
| US3948262A (en) | 1969-04-01 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3993073A (en) | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3967618A (en) | 1969-04-01 | 1976-07-06 | Alza Corporation | Drug delivery device |
| US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| US3734097A (en) | 1969-04-01 | 1973-05-22 | Alza Corp | Therapeutic adhesive tape |
| US3845761A (en) | 1970-06-02 | 1974-11-05 | Alza Corp | Intrauterine contraceptive anti-fertility device for the management of reproduction |
| US3737521A (en) | 1970-12-09 | 1973-06-05 | Goodrich Co B F | Formulation for sustained release of a biological agent |
| US3760805A (en) | 1971-01-13 | 1973-09-25 | Alza Corp | Osmotic dispenser with collapsible supply container |
| US4034756A (en) | 1971-01-13 | 1977-07-12 | Alza Corporation | Osmotically driven fluid dispenser |
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US3941880A (en) | 1971-02-22 | 1976-03-02 | G. D. Searle & Co. | Method for use of 11-lower alkyl steroids |
| US3731683A (en) | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
| US4041208A (en) | 1971-06-21 | 1977-08-09 | Ppg Industries, Inc. | Transparent, impact-resistant polyesterurethane laminates |
| US3881043A (en) | 1971-06-21 | 1975-04-29 | Ppg Industries Inc | Laminated safety windshields |
| US3931113A (en) | 1971-06-21 | 1976-01-06 | Ppg Industries, Inc. | Impact-resistant thermoplastic polyester urethanes |
| US3892842A (en) | 1971-09-01 | 1975-07-01 | Alza Corp | Intrauterine contraceptive device for releasing steroid having double bond functionality |
| US3948254A (en) | 1971-11-08 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3921636A (en) | 1973-01-15 | 1975-11-25 | Alza Corp | Novel drug delivery device |
| US3867933A (en) | 1973-03-06 | 1975-02-25 | Tecna Corp | Intrauterine device and process of making the same |
| US4036227A (en) | 1973-04-25 | 1977-07-19 | Alza Corporation | Osmotic releasing device having a plurality of release rate patterns |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| FR2250520B1 (en) | 1973-11-09 | 1977-04-15 | Cournut Rene | |
| US3901852A (en) | 1974-07-29 | 1975-08-26 | Upjohn Co | Thermoplastic polyurethanes prepared from 4,4'-methylenebis (phenyl isocyanate) |
| US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
| US4096238A (en) | 1974-12-23 | 1978-06-20 | Alza Corporation | Method for administering drug to the gastrointestinal tract |
| US4018918A (en) | 1975-05-20 | 1977-04-19 | The Upjohn Company | Topical clindamycin preparations |
| GB1479987A (en) | 1975-06-20 | 1977-07-13 | Interox Chemicals Ltd | Polyurethanes |
| US4235988A (en) | 1976-12-13 | 1980-11-25 | Imperial Chemical Industries Limited | Delivery means for biologically active agents |
| GB1551620A (en) | 1976-12-13 | 1979-08-30 | Ici Ltd | Delivery means for biologically active agents |
| US4289757A (en) | 1978-02-28 | 1981-09-15 | The Upjohn Company | Method for treating inflammation |
| US4205115A (en) | 1978-04-19 | 1980-05-27 | Ppg Industries, Inc. | Polyester coating composition |
| US4215691A (en) | 1978-10-11 | 1980-08-05 | Alza Corporation | Vaginal contraceptive system made from block copolymer |
| US4286587A (en) | 1978-10-11 | 1981-09-01 | Alza Corporation | Vaginal drug delivery system made from polymer |
| US4237885A (en) | 1978-10-23 | 1980-12-09 | Alza Corporation | Delivery system with mated members for storing and releasing a plurality of beneficial agents |
| WO1980001984A1 (en) | 1979-03-21 | 1980-10-02 | M Embrey | Controlled release compositions |
| US5079009A (en) | 1979-03-21 | 1992-01-07 | National Research Development Corporation | Controlled release compositions including polyethylene oxide with urethane cross-linking |
| US5017382A (en) | 1979-03-21 | 1991-05-21 | National Research Development Corporation | Controlled release compositions (II) |
| US4250611A (en) | 1979-04-19 | 1981-02-17 | Alza Corporation | Process for making drug delivery device with reservoir |
| US4264757A (en) | 1979-06-26 | 1981-04-28 | Union Carbide Corporation | Radiation-curable allyl- or vinyl capped polycaprolactone compositions |
| US4402695A (en) | 1980-01-21 | 1983-09-06 | Alza Corporation | Device for delivering agent in vagina |
| US4731289A (en) | 1980-02-14 | 1988-03-15 | Ppg Industries, Inc. | Abrasion resistant polyurethane coatings for rigid plastics |
| US4276405A (en) | 1980-03-28 | 1981-06-30 | Union Carbide Corporation | Low-energy-curable coatings compositions |
| DE3017989C2 (en) | 1980-05-10 | 1982-05-19 | IPOS Gesellschaft für integrierte Prothesen-Entwicklung und orthopädietechnischen Service mbH & Co KG, 2120 Lüneburg | "Collection bag for artificial intestinal exits" |
| US4466936A (en) | 1981-02-03 | 1984-08-21 | Bayer Aktiengesellschaft | Production of molds using gel compositions with depot action based on a polyurethane matrix and relatively high molecular weight polyols |
| AU558611B2 (en) | 1981-02-03 | 1987-02-05 | Bayer Aktiengesellschaft | Polyurethane gel |
| JPS57185313A (en) | 1981-05-08 | 1982-11-15 | Daicel Chem Ind Ltd | Polyurethane and its preparation |
| JPS57155230A (en) | 1981-02-27 | 1982-09-25 | Daicel Chem Ind Ltd | Lactone polymer having narrow molecular weight distribution and its preparation |
| US4426485A (en) | 1982-06-14 | 1984-01-17 | Union Carbide Corporation | Polymers with hydrophobe bunches |
| JPS5948409A (en) | 1982-09-10 | 1984-03-19 | Teikoku Seiyaku Kk | Promotor for orthodontic tooth mobility |
| US4438225A (en) | 1983-04-12 | 1984-03-20 | Henkel Corporation | Polyester polyols from bishydroxymethyl tricyclo compounds and caprolactone and polyurethanes based thereon |
| GB8319766D0 (en) | 1983-07-22 | 1983-08-24 | Graham N B | Controlled release device |
| FR2557576B1 (en) | 1984-01-03 | 1988-06-03 | Gould Francis | HYDROPHILIC POLYURETHANE ACRYLATE COMPOSITION, PREPARATION METHOD AND USE THEREOF AS BURNAGE DRESSING, IMPLANT, CONTRACEPTIVE, INTRA-UTERINE DEVICE, CANNULA, ORAL APPLICATION SYSTEM, GAS PERMEABLE MEMBRANE, CORNEAL PROSTHESIS, DRESSING DIALYSIS MEMBRANE, CONTACT LENS AND COATING OF SHIPS |
| US4694238A (en) | 1984-01-10 | 1987-09-15 | Peter Norton | Dual voltage power supply system for vehicles |
| GB8403138D0 (en) | 1984-02-07 | 1984-03-14 | Graham N B | Sustained release of active ingredient |
| US4503216A (en) | 1984-02-21 | 1985-03-05 | Eastman Kodak Company | Hydroxyl-terminated polyether-esters |
| US4568741A (en) | 1984-05-15 | 1986-02-04 | The Upjohn Company | Synthesis of 7-halo-7-deoxylincomycins |
| EP0180264A1 (en) | 1984-10-12 | 1986-05-07 | Akzo N.V. | Release system for two or more active substances |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| JPS61250019A (en) | 1985-04-27 | 1986-11-07 | Bridgestone Corp | Production of fine foam of polyurethane elastomer |
| JPS6257467A (en) | 1985-09-06 | 1987-03-13 | Asahi Glass Co Ltd | Coating agent composition |
| US4707495A (en) | 1985-10-28 | 1987-11-17 | Ortho Pharmaceutical | Peptic ulcer treatment method |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5731303A (en) | 1985-12-04 | 1998-03-24 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery compositions |
| US4917686A (en) | 1985-12-16 | 1990-04-17 | Colorado Biomedical, Inc. | Antimicrobial device and method |
| IE59361B1 (en) | 1986-01-24 | 1994-02-09 | Akzo Nv | Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension |
| US5219885A (en) | 1987-02-16 | 1993-06-15 | Froelich Juergen | Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration |
| US4804691A (en) | 1987-08-28 | 1989-02-14 | Richards Medical Company | Method for making a biodegradable adhesive for soft living tissue |
| EP0310037B1 (en) | 1987-09-28 | 1993-07-14 | Kuraray Co., Ltd. | Leather-like sheet material and method of producing same |
| US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
| JP2538953B2 (en) | 1987-11-17 | 1996-10-02 | 三菱重工業株式会社 | Balance mechanism of industrial robot |
| IE60383B1 (en) | 1988-05-27 | 1994-07-13 | Elan Corp Plc | Controlled release pharmaceutical formulation |
| US5219663A (en) | 1988-06-22 | 1993-06-15 | Hitachi Maxell, Ltd. | Magnetic recording medium having a magnetic layer formed from an aromatic polycarbonate polyurethane resin |
| JPH024736A (en) | 1988-06-22 | 1990-01-09 | Hitachi Maxell Ltd | Polycarbonate polyol, aromatic polycarbonate polyurethane resin, coating material, cast film and magnetic recording medium |
| JP2613441B2 (en) | 1988-07-18 | 1997-05-28 | トヨタ自動車株式会社 | Manufacturing method of foamed polyurethane |
| US5000955A (en) | 1988-07-29 | 1991-03-19 | Tyndale Plains-Hunter Ltd. | Thermally reversible polyurethane hydrogels and cosmetic, biological and medical uses |
| US4933418A (en) | 1988-08-10 | 1990-06-12 | Ormco Corporation | Stain-resistant orthodontic device |
| US4895934A (en) | 1988-08-22 | 1990-01-23 | E. I. Du Pont De Nemours And Company | Process for the preparation of clindamycin phosphate |
| SE463851B (en) | 1988-09-02 | 1991-02-04 | Amsu Ltd | COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA |
| US5470829A (en) | 1988-11-17 | 1995-11-28 | Prisell; Per | Pharmaceutical preparation |
| FR2641786B1 (en) | 1989-01-19 | 1992-09-11 | Sami | URETHANE POLYMER COMPOSITION AND PREPARATION OF ARTICLES THEREFROM |
| DE3903538A1 (en) | 1989-02-07 | 1990-08-16 | Basf Ag | PRODUCTION OF EMULSIFIER-FREE, AQUEOUS POLYURETHANE DISPERSIONS |
| ES2010145A6 (en) | 1989-03-02 | 1989-10-16 | Uriach & Cia Sa J | 2-picolylamine derivates. |
| US5888930A (en) | 1989-03-27 | 1999-03-30 | Bend Research, Inc. | Asymmetric microporous beads for controlled release |
| US5002540A (en) | 1989-05-22 | 1991-03-26 | Warren Kirschbaum | Intravaginal device and method for delivering a medicament |
| US5034461A (en) | 1989-06-07 | 1991-07-23 | Bausch & Lomb Incorporated | Novel prepolymers useful in biomedical devices |
| US5061254A (en) | 1989-06-21 | 1991-10-29 | Becton, Dickinson And Company | Thermoplastic elastomeric hydrophilic polyetherurethane expandable catheter |
| US5178874A (en) | 1989-06-30 | 1993-01-12 | Smithkline Beechman Corporation | Intermittent release dosage form |
| US5110598A (en) | 1989-06-30 | 1992-05-05 | Smithkline Beecham Corp. | Intermittent release dosage form |
| JP2844474B2 (en) | 1989-07-19 | 1999-01-06 | ダイセル化学工業株式会社 | Method for producing polyurethane |
| GB8918589D0 (en) * | 1989-08-15 | 1989-09-27 | Graham Neil B | Polymeric compositions |
| US5118779A (en) | 1989-10-10 | 1992-06-02 | Polymedica Industries, Inc. | Hydrophilic polyurethane elastomers |
| DE4006521A1 (en) | 1990-03-02 | 1991-09-05 | Bayer Ag | SUGAR-BASED POLYMERS FOR COATING AND EMBEDDING MEDICINAL SUBSTANCES |
| DE4019171A1 (en) | 1990-06-15 | 1991-12-19 | Henkel Kgaa | COATING AGENT |
| GB2244920B (en) | 1990-06-16 | 1994-05-25 | British Aerospace | A contraceptive device |
| US5130126A (en) | 1990-07-09 | 1992-07-14 | Nippon Oil & Fats Co., Ltd. | Polymer-drug conjugate and a method of producing it |
| ES2084825T3 (en) | 1990-07-26 | 1996-05-16 | Monsanto Co | PROCEDURE FOR THE PREPARATION OF CROSS-LINKED POLYAMIDES. |
| US5326632A (en) | 1990-08-07 | 1994-07-05 | Komatsu Seiren Co., Ltd. | Moisture-permeable waterproof fabric and process for production thereof |
| US5114718A (en) | 1990-09-20 | 1992-05-19 | The Procter & Gamble Company | Sustained release compositions for treating periodontol disease |
| JPH05239205A (en) | 1991-02-13 | 1993-09-17 | Ajinomoto Co Inc | Poly(amino acid-urethane) resin |
| GB2254002B (en) | 1991-01-16 | 1995-03-22 | Controlled Therapeutics | Retrievable pessary |
| US5652274A (en) | 1991-03-01 | 1997-07-29 | Martin; Alain | Therapeutic-wound healing compositions and methods for preparing and using same |
| US5159047A (en) | 1991-06-14 | 1992-10-27 | E. I. Du Pont De Nemours And Company | Coatings containing caprolactone oligomer polyols |
| CA2071137A1 (en) | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
| US5176907A (en) | 1991-08-13 | 1993-01-05 | The Johns Hopkins University School Of Medicine | Biocompatible and biodegradable poly (phosphoester-urethanes) |
| US5322063A (en) | 1991-10-04 | 1994-06-21 | Eli Lilly And Company | Hydrophilic polyurethane membranes for electrochemical glucose sensors |
| US5252602A (en) | 1991-10-11 | 1993-10-12 | Rafeul Alam | Effects of misoprostol on allergic responses |
| HUT74560A (en) | 1991-10-16 | 1997-01-28 | Richardson Vicks Inc | Enhanced skin penetration system for improved topical delivery of drugs |
| US6117843A (en) | 1992-02-18 | 2000-09-12 | Lloyd J. Baroody | Compositions for the treatment of acne containing clindamycin and benzoyl peroxide |
| US5650171A (en) | 1992-04-29 | 1997-07-22 | Penederm, Inc. | Retinoic acid-containing polyether-polyurethane compositions |
| US5578643A (en) | 1992-05-20 | 1996-11-26 | Loyola University Of Chicago | Protective prostaglandins for use in conjunction with chemotherapeutic agents |
| JP3119533B2 (en) | 1992-05-27 | 2000-12-25 | 日本ペイント株式会社 | Chipping resistant coating composition |
| US5710215A (en) | 1992-06-15 | 1998-01-20 | Ebnother Ag | Method and material mixture for manufacture of reactive hotmelts |
| US5310759A (en) | 1992-08-12 | 1994-05-10 | Bockman Richard S | Methods of protecting and preserving connective and support tissues |
| US6328991B1 (en) | 1992-10-21 | 2001-12-11 | John Myhling | Composition and method for prevention of sexually transmitted diseases, including aids |
| EP0665733B1 (en) | 1992-10-21 | 2003-05-07 | Gynetech Laboratories, Inc. | Vaginal sponge delivery system |
| US5747582A (en) | 1992-10-29 | 1998-05-05 | Bayer Aktiengesellschaft | Aqueous coating compositions and their use for the preparation of coatings that are permeable to water vapor |
| DE4241118A1 (en) | 1992-12-07 | 1994-06-09 | Basf Ag | Use of cationic polyurethanes and polyureas as auxiliaries in cosmetic and pharmaceutical preparations |
| DE4242687B8 (en) | 1992-12-17 | 2006-01-12 | Henkel Kgaa | Hydrophilic polyurethanes |
| DE4315173A1 (en) | 1992-12-23 | 1994-06-30 | Bayer Ag | Pure, especially catalyst-free polyurethanes |
| US5324746A (en) | 1993-02-12 | 1994-06-28 | Mckee Rex N | Method of treating damaged mucosal and epithelial tissues with misoprostol |
| GB9306887D0 (en) * | 1993-04-01 | 1993-05-26 | Graham Neil B | Random block copolymers |
| US5328954A (en) | 1993-04-16 | 1994-07-12 | Icet, Inc. | Encrusting and bacterial resistant coatings for medical applications |
| FR2705567A1 (en) | 1993-05-25 | 1994-12-02 | Smith & Nephew Laboratoires Fi | Microparticles, preparation process and application to dressings |
| US5723552A (en) | 1994-12-21 | 1998-03-03 | Basf Corporation | Polyurethane polymer or oligomer having carbamate groups, method for its preparation, and coating composition |
| US5770650A (en) | 1995-10-06 | 1998-06-23 | Basf Corporation | Curable compositions for coatings |
| US5994479A (en) | 1993-07-28 | 1999-11-30 | Basf Corporation | Curable coating compositions containing blends of carbamate-functional compounds |
| US5827930A (en) | 1995-10-06 | 1998-10-27 | Basf Corporation | Curable coating composition |
| US5777048A (en) | 1996-06-20 | 1998-07-07 | Basf Corporation | Method for modified aminoplast compounds, aminoplasts obtained thereby and coatings containing the same |
| US5854385A (en) | 1995-10-06 | 1998-12-29 | Basf Corporation | Coating compositions with low molecular weight carbamate or urea component |
| US6084038A (en) | 1993-07-28 | 2000-07-04 | Basf Corporation | Curable coating compositions containing blends of carbamate-functional compounds |
| US5726244A (en) | 1995-08-10 | 1998-03-10 | Basf Corporation | Aqueous coating compositions for environmental etch resistant coatings |
| US5792810A (en) | 1995-10-06 | 1998-08-11 | Basf Corporation | Curable coating composition including compound having carbamate and hydroxyl functionality |
| US5744550A (en) | 1994-11-03 | 1998-04-28 | Basf Corporation | Curable coating compositions containing carbamate additives |
| US6160058A (en) | 1993-07-28 | 2000-12-12 | Basf Corporation | Curable coating compositions containing blends of carbamate-functional compounds |
| US6080825A (en) | 1993-07-28 | 2000-06-27 | Basf Corporation | Curable coating compositions containing blends of carbamate-functional compounds |
| US6423788B1 (en) | 1995-10-06 | 2002-07-23 | Basf Corporation | Curable coating composition |
| DE69405939T2 (en) | 1993-07-28 | 1998-05-07 | Basf Corp | Curable polyureas |
| JPH0753663A (en) * | 1993-07-30 | 1995-02-28 | Takiron Co Ltd | Base polymer for percutaneous absorption preparation |
| US5514698A (en) | 1994-03-21 | 1996-05-07 | Ortho Pharmaceutical Corporation | Antifungal vaginal cream composition |
| US5472785A (en) | 1994-04-12 | 1995-12-05 | Minnesota Mining And Manufacturing Company | Reactive wax-containing moisture curable hot melt composition |
| US5985859A (en) | 1994-04-14 | 1999-11-16 | The University Of Alabama | Methods of inhibiting bacterial sialidase |
| IL109539A0 (en) | 1994-05-03 | 1994-08-26 | Yissum Res Dev Co | Substained-release pharmaceutical system for the delivery of antioxidants |
| CZ345096A3 (en) | 1994-05-25 | 1997-09-17 | Henkel Kgaa | iN MOISTURE CONDITIONS HARDENING POLYURETHANE FUSIBLE ADHESIVE |
| US5681278A (en) | 1994-06-23 | 1997-10-28 | Cormedics Corp. | Coronary vasculature treatment method |
| GB9419566D0 (en) | 1994-09-27 | 1994-11-16 | El Refaey Hazem | Oral prostagladins for the routine management of the third stage of labour |
| IL116433A (en) | 1994-12-19 | 2002-02-10 | Galen Chemicals Ltd | INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS |
| US20030158369A1 (en) | 1995-02-02 | 2003-08-21 | Slagel Edwin C. | Impact resistant polyurethane and method of manufacture thereof |
| GB9506946D0 (en) | 1995-04-04 | 1995-05-24 | Univ Strathclyde | Microgels |
| JPH11511774A (en) | 1995-05-26 | 1999-10-12 | ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチエン | Join method |
| PT828495E (en) | 1995-06-01 | 2003-01-31 | Searle & Co | MISOPROSTOL STABILIZED SOLID SCATTERS |
| US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
| US7833543B2 (en) | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
| US5733538A (en) | 1995-06-07 | 1998-03-31 | Thoratec Laboratories, Inc. | Surface-modifying copolymers having cell adhesion properties |
| US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
| US5900433A (en) | 1995-06-23 | 1999-05-04 | Cormedics Corp. | Vascular treatment method and apparatus |
| US5948416A (en) | 1995-06-29 | 1999-09-07 | The Procter & Gamble Company | Stable topical compositions |
| JPH11510837A (en) | 1995-07-28 | 1999-09-21 | フォーカル，インコーポレイテッド | Multi-block biodegradable hydrogels for use as controlled release and tissue treatment agents for drug delivery |
| CN1195990A (en) | 1995-09-13 | 1998-10-14 | 日本新药株式会社 | PGE1-containing freeze-dried preparation and process for production thereof |
| DE19541658A1 (en) | 1995-11-08 | 1997-05-15 | Basf Ag | Water-soluble or water-dispersible graft polymers, their preparation and their use |
| US6008312A (en) | 1995-12-01 | 1999-12-28 | Hokushin Corp | Method for producing millable polyurethanes and polyurethane elastomers |
| EP0776921A3 (en) | 1995-12-01 | 1997-08-13 | Hokushin Corp | Method for preparing amorphous polymer chains in elastomers |
| EP0869772B1 (en) | 1995-12-27 | 2001-10-04 | Janssen Pharmaceutica N.V. | Bioadhesive solid dosage form |
| US6521164B1 (en) | 1996-02-06 | 2003-02-18 | Parker-Hannifin Corporation | Injection-moldable thermoplastic polyurethane elastomer |
| US5627254A (en) | 1996-05-03 | 1997-05-06 | The Dow Chemical Company | Rigid thermoplastic plyurethane comprising units of butane diol and a polyethylene glycol |
| US5817343A (en) | 1996-05-14 | 1998-10-06 | Alkermes, Inc. | Method for fabricating polymer-based controlled-release devices |
| AU733800B2 (en) | 1996-07-01 | 2001-05-24 | Basf Corporation | Curable coating compositions containing carbamate additives |
| US5972372A (en) | 1996-07-31 | 1999-10-26 | The Population Council, Inc. | Intravaginal rings with insertable drug-containing core |
| US6043224A (en) | 1996-09-05 | 2000-03-28 | The Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| US6184248B1 (en) | 1996-09-05 | 2001-02-06 | Robert K. K. Lee | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| DE19638570A1 (en) | 1996-09-20 | 1998-03-26 | Bayer Ag | Active ingredient-containing thermoplastic polyurethanes |
| US6130309A (en) | 1996-09-20 | 2000-10-10 | Tyndale Plains-Hunter, Ltd. | Hydrophilic polyether polyurethanes containing carboxylic acid |
| NZ335208A (en) | 1996-11-04 | 2000-11-24 | Huntsman Ici Chem Llc | Rigid polyurethane foams |
| DK0959873T3 (en) | 1996-12-20 | 2006-07-03 | Alza Corp | Gel composition and methods |
| US5853767A (en) | 1997-01-02 | 1998-12-29 | Melman; Steven A. | Compositions for treating fungal, parasitic and/or bacterial infections, especially infections of organs such as the skin and vagina |
| US20050208152A1 (en) | 1997-01-22 | 2005-09-22 | Marton Milankovits | Pharmaceutical compositions primarily for the treatment and prevention of genitourinary infections and their extragenital complications |
| US6471955B1 (en) | 1997-04-04 | 2002-10-29 | Pharmacia Corporation | Ph-selective delivery system using crosslinked polymeric resins as vehicles |
| US6221997B1 (en) | 1997-04-28 | 2001-04-24 | Kimberly Ann Woodhouse | Biodegradable polyurethanes |
| US20020115814A1 (en) | 1997-04-28 | 2002-08-22 | Woodhouse Kimberly Ann | Incorporation by reference of co-pending application |
| GR1002847B (en) | 1997-05-06 | 1998-01-27 | Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic treatiment of problems related to the erection | |
| JPH10332902A (en) | 1997-05-27 | 1998-12-18 | Nippon Ee R C Kk | Plastic lens, its production and primer composition |
| US6197327B1 (en) | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
| ES2123466B1 (en) | 1997-06-11 | 1999-11-16 | Merquinsa Mercados Quimicos S | THERMOPLASTIC OF POLYURETHANE AND PROCEDURE FOR ITS OBTAINING. |
| US6416779B1 (en) | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
| US6572874B1 (en) | 1998-05-15 | 2003-06-03 | Umd, Inc. | Vaginal delivery of bisphosphonates |
| US6039968A (en) | 1997-06-24 | 2000-03-21 | Hoechst Marion Roussel | Intravaginal drug delivery device |
| EP1005336A4 (en) | 1997-07-09 | 2001-01-17 | Androsolutions Inc | Improved methods and compositions for treating male erectile dysfunction |
| US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
| WO1999010403A1 (en) | 1997-08-25 | 1999-03-04 | Union Carbide Chemicals & Plastics Technology Corporation | Condensation copolymers having surpressed crystallinity |
| DE19737348C2 (en) | 1997-08-27 | 2002-07-25 | Dan-Gabriel Vulpescu | Pharmaceutical composition containing clindamycin and clotrimazole |
| DE19742217A1 (en) | 1997-09-24 | 1999-04-01 | Henkel Kgaa | Polyurethane for thermally removable label adhesive |
| ATE237650T1 (en) * | 1997-09-24 | 2003-05-15 | Henkel Kgaa | POLYURETHANE ADHESIVE |
| DE19744473A1 (en) | 1997-10-09 | 1999-04-15 | Basf Ag | Use of water-soluble or water-dispersible polyurethanes as coating agents or binders for pharmaceutical dosage forms |
| US20020004529A1 (en) | 1997-10-20 | 2002-01-10 | Gary W. Neal | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
| US6593369B2 (en) | 1997-10-20 | 2003-07-15 | Vivus, Inc. | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
| US20040044080A1 (en) | 1997-10-28 | 2004-03-04 | Place Virgil A. | Treatment of dyspareunia with topically administered nitroglycerin formulations |
| US20020013304A1 (en) | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| WO1999021562A1 (en) | 1997-10-28 | 1999-05-06 | Asivi, Llc | Treatment of female sexual dysfunction |
| US20040014761A1 (en) | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
| US20020099003A1 (en) | 1997-10-28 | 2002-07-25 | Wilson Leland F. | Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof |
| US20050070516A1 (en) | 1997-10-28 | 2005-03-31 | Vivus Inc. | As-needed administration of an androgenic agent to enhance female desire and responsiveness |
| US6414028B1 (en) | 1997-11-05 | 2002-07-02 | Nexmed Holdings, Inc. | Topical compositions containing prostaglandin E1 |
| US6046244A (en) | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
| AU1137899A (en) | 1997-11-17 | 1999-06-07 | Cosma International Inc. | Projection welded panel spacer and method of making the same |
| ES2138918B1 (en) | 1997-11-20 | 2000-09-16 | Merquinsa Mercados Quimicos S | THERMOPLASTIC OF CRYSTALLINE POLYURETHANE AND METHOD FOR ITS OBTAINING. |
| US6022554A (en) | 1997-12-15 | 2000-02-08 | American Home Products Corporation | Polymeric microporous film coated subcutaneous implant |
| DE19757569A1 (en) | 1997-12-23 | 1999-06-24 | Bayer Ag | Thermoplastic polyurethane molding composition giving little condensate, for surface cladding on vehicles |
| US5959775A (en) | 1997-12-23 | 1999-09-28 | 3M Innovative Properties Company | Urethane/acrylate bead bond for retroreflective articles |
| DK1051437T3 (en) * | 1998-01-28 | 2005-09-19 | Bristol Myers Squibb Co | Process for producing polyurethane adhesives and adhesives made thereby |
| US6028057A (en) | 1998-02-19 | 2000-02-22 | Thorn Bioscience, Llc | Regulation of estrus and ovulation in gilts |
| KR100684055B1 (en) | 1998-03-19 | 2007-02-16 | 머크 앤드 캄파니 인코포레이티드 | Liquid polymeric compositions for controlled release of bioactive substances |
| US5891915A (en) | 1998-05-01 | 1999-04-06 | Wysor; Michael S. | Method for enhancing female sexual response and an ointment therefor |
| US6031002A (en) | 1998-05-01 | 2000-02-29 | Michael Ebert | Method for enhancing female sexual response and a composition therefor |
| US6013637A (en) | 1998-06-12 | 2000-01-11 | Dermik Laboratories Inc. | Anti-acne method and composition |
| US5942545A (en) | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
| DE19847791A1 (en) | 1998-10-16 | 2000-04-20 | Bayer Ag | Aqueous polyurethane dispersions |
| NL1010367C2 (en) | 1998-10-21 | 2000-04-25 | Akzo Nobel Nv | Water vapor permeable thermoplastic polyurethane film. |
| DE19849499A1 (en) | 1998-10-27 | 2000-05-04 | Basf Ag | Process for the complete drying of hydrogels |
| GB9826192D0 (en) | 1998-12-01 | 1999-01-20 | Controlled Theraputics Scotlan | Oral transmucosal delivery |
| US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US20050004226A1 (en) | 1998-12-10 | 2005-01-06 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| DE10004723A1 (en) | 2000-02-03 | 2001-08-09 | Bayer Ag | Aqueous barrier layer based on polyurethane dispersions |
| US6545119B2 (en) | 1999-03-08 | 2003-04-08 | Toyo Boseki Kabushiki Kaisha | Magnetic recording media and thermoplastic polyurethane resins therefor |
| ATE302598T1 (en) | 1999-04-01 | 2005-09-15 | Alza Corp | TRANSDERMAL DRUG ADMINISTRATION DEVICE HAVING A POLYURETHANE DRUG RESERVOIR |
| DE19915932A1 (en) | 1999-04-09 | 2000-10-19 | Freudenberg Carl Fa | Thermoplastic processable polyurethane molding compound |
| US6117024A (en) | 1999-04-20 | 2000-09-12 | Callaway Golf Company | Golf ball with polyurethane cover |
| US6607686B2 (en) | 1999-04-20 | 2003-08-19 | Callaway Golf Company | Thermosetting polyurethane material for a golf ball |
| US6592472B2 (en) | 1999-04-20 | 2003-07-15 | Callaway Golf Company | Golf ball having a non-yellowing cover |
| IT1312310B1 (en) | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | USE OF SELECTIVE 1B ADRENERGIC RECEPTOR ANTAGONISTS TO IMPROVE SEXUAL DYSFUNCTION |
| TWI232111B (en) | 1999-08-06 | 2005-05-11 | Upjohn Co | Intravaginal clindamycin ovule composition |
| US6642274B1 (en) | 1999-09-09 | 2003-11-04 | Gary W. Neal | Methods and compositions for preventing and treating prostate disorders |
| US6693135B2 (en) | 2000-01-10 | 2004-02-17 | Nexmed (Holdings) Incorporated | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| US20040110843A1 (en) | 2000-01-10 | 2004-06-10 | Nexmed (Holdings), Inc. | Methods of treatment of male erectile dysfunction |
| US7105571B2 (en) | 2000-01-10 | 2006-09-12 | Nexmed Holdings, Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| US6323241B1 (en) | 2000-01-10 | 2001-11-27 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| IT1317735B1 (en) | 2000-01-26 | 2003-07-15 | Nicox Sa | SALTS OF ANTIMICROBIAL AGENTS. |
| DE10028810A1 (en) | 2000-06-10 | 2001-12-20 | Henkel Kgaa | Polyurethane melt adhesive composition, useful for the adhesion of leather, plastic, wood and glass, comprises a product of a polyisocyanate with a polyester block copolymer |
| US6803495B2 (en) | 2000-06-28 | 2004-10-12 | World Properties, Inc. | Polyurethane foam composition and method of manufacture thereof |
| US20040047910A1 (en) | 2000-07-07 | 2004-03-11 | Christian Beckett | Suppository and composition comprising at least one polyethylene glycol |
| JP4378667B2 (en) * | 2000-09-11 | 2009-12-09 | 東レ・オペロンテックス株式会社 | Method for producing polyurethane fiber |
| DE10050137A1 (en) | 2000-10-11 | 2002-04-18 | Bayer Ag | Stabilized mono- and polyaspartic acid esters |
| DE10051392A1 (en) | 2000-10-17 | 2002-04-18 | Bayer Ag | Binder for preparation of electrically insulating lacquers comprises specific polyurethane(s), organic solvents, and optional adjuvants and additives |
| JP5027962B2 (en) | 2000-10-19 | 2012-09-19 | Ｄｉｃ株式会社 | Method for producing liquid urethane prepolymer and resin composition |
| US6811549B2 (en) | 2001-02-16 | 2004-11-02 | William H. Fleming | Administration of therapeutic or diagnostic agents using interlabial pad |
| DE10112366B4 (en) | 2001-03-15 | 2006-06-08 | Bayer Materialscience Ag | Aliphatic thermoplastic polyurethanes and their use |
| US6881788B2 (en) | 2001-08-21 | 2005-04-19 | Mitsui Takeda Chemicals, Inc. | Polyurethane resin water dispersion and aqueous polyurethane adhesive |
| WO2003059373A2 (en) | 2002-01-16 | 2003-07-24 | Ramot At Tel Aviv University Ltd. | Compositions and their use for enhancing and inhibiting fertilization |
| CH697081A5 (en) | 2002-01-22 | 2008-04-30 | Andreas F Dr Schaub | Composition for supporting the birth of a human fetuses. |
| NZ517094A (en) | 2002-02-08 | 2005-03-24 | Advanced Animal Technology Ltd | Improvements in and relating to substance delivery device |
| EP1474069A1 (en) | 2002-02-08 | 2004-11-10 | Advanced Animal Technology Limited | Control of a biological function |
| US6861503B2 (en) | 2002-02-27 | 2005-03-01 | Poly-Med, Inc. | Interlinked solid polyethylene glycols and copolymers thereof |
| US7358295B2 (en) | 2002-04-05 | 2008-04-15 | Lubrizol Advanced Materials, Inc. | Hybrid polymer composition, and article therefrom |
| FR2840907B1 (en) * | 2002-06-14 | 2005-11-25 | Polymerexpert Sa | ENHANCED THERMO-SENSITIVE POLYMER CAPABLE OF FORMING HIGH VISCOSIFICATION INJECTABLE THERMOREVERSIBLE GELS |
| US7179481B2 (en) | 2002-09-19 | 2007-02-20 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
| GB0222522D0 (en) * | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
| WO2004039323A2 (en) | 2002-10-28 | 2004-05-13 | Tyco Healthcare Group Lp | Fast curing compositions |
| US20040142847A1 (en) | 2002-11-21 | 2004-07-22 | Rolf Bayersdoerfer | Detergent tablets with polyurethane coating |
| US20050181030A1 (en) | 2003-01-03 | 2005-08-18 | Mo Y. J. | Topical stabilized prostaglandin E compound dosage forms |
| US6841574B2 (en) | 2003-01-03 | 2005-01-11 | Nexmed Holdings, Inc. | Topical stabilized prostaglandin E compound dosage forms |
| EP1592728A2 (en) | 2003-01-16 | 2005-11-09 | Carnegie-Mellon University | Biodegradable polyurethanes and use thereof |
| GB0301577D0 (en) | 2003-01-23 | 2003-02-26 | Edko Pazarlama Tanitim Ltd Sti | Topical pharmaceutical and/or cosmetic dispense systems |
| GB0306977D0 (en) | 2003-03-26 | 2003-04-30 | Metris Therapeutics Ltd | Device |
| WO2004091579A1 (en) | 2003-04-16 | 2004-10-28 | Pharmacia Corporation | Stabilized prostaglandin formulation |
| ATE461681T1 (en) | 2003-04-29 | 2010-04-15 | Gen Hospital Corp | METHODS AND DEVICES FOR SUSTAINED RELEASE OF MULTIPLE DRUGS |
| WO2004103159A2 (en) | 2003-05-14 | 2004-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modulating endometrium |
| US8399013B2 (en) | 2003-06-26 | 2013-03-19 | Poly-Med, Inc. | Partially absorbable fiber-reinforced composites for controlled drug delivery |
| US8404272B2 (en) | 2003-06-26 | 2013-03-26 | Poly-Med, Inc. | Fiber-reinforced composite rings for intravaginal controlled drug delivery |
| CN1822815B (en) | 2003-07-10 | 2012-04-11 | 沃纳奇尔科特(爱尔兰)有限公司 | Intravaginal drug delivery devices |
| US20060018951A1 (en) | 2003-08-08 | 2006-01-26 | Sri International | pH-responsive film for intravaginal delivery of a beneficial agent |
| US20050095245A1 (en) | 2003-09-19 | 2005-05-05 | Riley Thomas C. | Pharmaceutical delivery system |
| EP1506781B1 (en) | 2003-11-03 | 2005-02-23 | Peter-Hansen Volkmann | Vaginal care composition |
| EP1555278A1 (en) | 2004-01-15 | 2005-07-20 | Innocore Technologies B.V. | Biodegradable multi-block co-polymers |
| CA2549701C (en) | 2004-01-28 | 2009-07-28 | New Condensator, Inc. | Apparatus for removing contaminants from crankcase emissions |
| AU2005200368A1 (en) | 2004-02-03 | 2005-08-18 | Nitto Denko Corporation | Film base material for adhesive skin patch and adhesive skin patch |
| DE102004008015A1 (en) | 2004-02-19 | 2005-09-08 | Cognis Deutschland Gmbh & Co. Kg | Thickener for polyurethane base |
| CN1950098B (en) | 2004-03-24 | 2013-02-27 | 宝利诺沃生物材料有限公司 | Biodegradable polyurethane and polyurethane ureas |
| EP1737500A1 (en) | 2004-03-26 | 2007-01-03 | The University of Utah Research Foundation | Bioresponsive polymer system for delivery of microbicides |
| EP1741454B1 (en) | 2004-03-29 | 2011-06-29 | Sanyo Chemical Industries, Ltd. | Medical adhesive |
| CA2563923A1 (en) | 2004-04-15 | 2005-10-27 | The University Of Utah Research Foundation | Biodegradable and biocompatible peg-based poly(ester-urethanes) |
| US7485666B2 (en) | 2004-06-17 | 2009-02-03 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
| US20060003950A1 (en) | 2004-06-30 | 2006-01-05 | Bone Care International, Inc. | Method of treating prostatic diseases using a combination of vitamin D analogues and other agents |
| DE102004031786A1 (en) | 2004-07-01 | 2006-01-26 | Cognis Deutschland Gmbh & Co. Kg | Polyurethane-based thickener |
| DE602005026290D1 (en) | 2004-07-09 | 2011-03-24 | Population Council Inc | COMPOSITIONS OF DELAYED RELEASE WITH PROGESTERONE RECEPTOR MODULATORS |
| WO2006010278A1 (en) | 2004-07-26 | 2006-02-02 | Synthes Gmbh | Biocompatible, biodegradable polyurethane materials with controlled hydrophobic to hydrophilic ratio |
| GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
| US20060078616A1 (en) | 2004-08-30 | 2006-04-13 | Georgewill Dawaye A | Thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol |
| US20060093675A1 (en) | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
| GB0424526D0 (en) | 2004-11-05 | 2004-12-08 | Controlled Therapeutics Sct | Hydrogel delivery vehicle |
| EP1853272A1 (en) | 2005-02-03 | 2007-11-14 | Duramed Pharmaceuticals, Inc. | Compositions of unconjugated estrogens and methods for their use |
| US7795467B1 (en) * | 2005-04-26 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial polyurethanes for use in medical devices |
| TW200744610A (en) | 2005-06-21 | 2007-12-16 | Organon Nv | New regimens for controlled drug delivery devices for contraception |
| TW200727920A (en) | 2005-06-21 | 2007-08-01 | Organon Nv | New regimens for oral monophasic contraceptives |
| CA2615393C (en) | 2005-07-19 | 2011-09-20 | The Population Council, Inc. | Methods and compositions for emergency contraception using endothelin receptor antagonists |
| JP2009518129A (en) | 2005-12-06 | 2009-05-07 | タイコ ヘルスケア グループ リミテッド パートナーシップ | Bioabsorbable surgical composition |
| WO2007067806A2 (en) | 2005-12-08 | 2007-06-14 | Tyco Healthcare Group Lp | Biocompatible surgical compositons |
| US20070148105A1 (en) | 2005-12-22 | 2007-06-28 | Donald Spector | Compositions and methods comprising magnetic particles for health use |
| US20090061172A1 (en) | 2006-01-26 | 2009-03-05 | Komatsu Seiren Co., Ltd. | Polyurethane Resin Composition for Durable Moisture-Permeable Waterproof Sheet, Moisture-Permeable Waterproof Sheet and Method of Manufacturing the Same |
| WO2007101808A1 (en) | 2006-03-06 | 2007-09-13 | Basf Se | Nonwoven based on thermoplastic polyurethane |
| US20100285094A1 (en) | 2006-04-20 | 2010-11-11 | University Of Utah Research Foundation | Polymeric compositions and methods of making and using thereof |
| GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
| US8047980B2 (en) | 2006-07-10 | 2011-11-01 | Mcneil-Ppc, Inc. | Method of treating urinary incontinence |
| JP2009542788A (en) | 2006-07-12 | 2009-12-03 | コントロールド・セラピューティクス（スコットランド）・リミテッド | Drug delivery polymer with clindamycin hydrochloride |
| MX2009005445A (en) | 2006-11-22 | 2009-06-02 | Organon Nv | Delivery system for risperidone. |
| US7781651B2 (en) | 2007-04-30 | 2010-08-24 | Monsanto Technology Llc | Plants and seeds of corn variety CV715590 |
| SG195525A1 (en) | 2007-06-26 | 2013-12-30 | Warner Chilcott Co Llc | Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs |
| US20110059040A1 (en) | 2007-06-27 | 2011-03-10 | Kiser Patrick F | Compositions and methods for inhibiting viral and bacterial activity |
| AR066166A1 (en) | 2007-09-21 | 2009-07-29 | Organon Nv | DRUG SUPPLY SYSTEM |
| US8660175B2 (en) | 2007-12-10 | 2014-02-25 | Qualcomm Incorporated | Selective display of interpolated or extrapolated video units |
| EP2244782A4 (en) | 2008-01-25 | 2011-09-14 | Univ Utah Res Found | Linear order release polymer |
| FI20085277A0 (en) | 2008-04-02 | 2008-04-02 | Bayer Schering Pharma Oy | Intrauterine system |
| US20110150955A1 (en) | 2009-12-23 | 2011-06-23 | Shannon Elizabeth Klingman | Products and Methods for Reducing Malodor from the Pudendum |
-
2006
- 2006-07-08 GB GBGB0613638.6A patent/GB0613638D0/en not_active Ceased
-
2007
- 2007-06-27 DE DE602007012545T patent/DE602007012545D1/en active Active
- 2007-06-27 BR BRPI0713481A patent/BRPI0713481B8/en active IP Right Grant
- 2007-06-27 US US12/373,002 patent/US8361272B2/en active Active
- 2007-06-27 EP EP07733405A patent/EP2038325B1/en active Active
- 2007-06-27 ES ES07733405T patent/ES2363704T3/en active Active
- 2007-06-27 CN CN2007800256285A patent/CN101484495B/en active Active
- 2007-06-27 AU AU2007274119A patent/AU2007274119B2/en active Active
- 2007-06-27 PL PL07733405T patent/PL2038325T3/en unknown
- 2007-06-27 JP JP2009517399A patent/JP5307710B2/en active Active
- 2007-06-27 AT AT07733405T patent/ATE498643T1/en active
- 2007-06-27 DK DK07733405.0T patent/DK2038325T3/en active
- 2007-06-27 WO PCT/GB2007/002415 patent/WO2008007046A1/en active Application Filing
- 2007-06-27 CA CA2656788A patent/CA2656788C/en active Active
- 2007-06-27 PT PT07733405T patent/PT2038325E/en unknown
-
2012
- 2012-09-06 US US13/605,689 patent/US8361273B2/en active Active
-
2013
- 2013-03-05 JP JP2013043282A patent/JP5639673B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013151517A (en) | 2013-08-08 |
| PL2038325T3 (en) | 2011-07-29 |
| AU2007274119A1 (en) | 2008-01-17 |
| CN101484495A (en) | 2009-07-15 |
| AU2007274119B2 (en) | 2013-01-31 |
| ES2363704T3 (en) | 2011-08-12 |
| US8361272B2 (en) | 2013-01-29 |
| US20120329883A1 (en) | 2012-12-27 |
| ATE498643T1 (en) | 2011-03-15 |
| CN101484495B (en) | 2011-12-28 |
| JP5307710B2 (en) | 2013-10-02 |
| CA2656788C (en) | 2015-01-27 |
| JP5639673B2 (en) | 2014-12-10 |
| WO2008007046A1 (en) | 2008-01-17 |
| BRPI0713481A2 (en) | 2012-11-06 |
| US20090324692A1 (en) | 2009-12-31 |
| PT2038325E (en) | 2011-05-02 |
| GB0613638D0 (en) | 2006-08-16 |
| JP2009542831A (en) | 2009-12-03 |
| EP2038325A1 (en) | 2009-03-25 |
| EP2038325B1 (en) | 2011-02-16 |
| DE602007012545D1 (en) | 2011-03-31 |
| DK2038325T3 (en) | 2011-05-30 |
| BRPI0713481B1 (en) | 2019-08-13 |
| BRPI0713481B8 (en) | 2021-05-25 |
| US8361273B2 (en) | 2013-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2656788C (en) | Controlled release composition comprising polyurethane elastomers | |
| US10105445B2 (en) | Hydrophilic polyurethane compositions | |
| EP2520280A2 (en) | Water-swellable polymer with misoprostol | |
| EP2076556B1 (en) | Bioresorbable polymers | |
| AU2013205539B2 (en) | Polyurethane elastomers | |
| EP3017809A1 (en) | Drug-device unit containing quinagolide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |